<pmc-articleset xmlns:ns0="http://www.niso.org/schemas/ali/1.0/" xmlns:ns1="http://www.w3.org/1999/xlink"><article dtd-version="1.3" xml:lang="en" article-type="research-article">
  
  
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">101573691</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">39703</journal-id>
      <journal-id journal-id-type="nlm-ta">Cell Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Cell Rep</journal-id>
      <journal-title-group>
        <journal-title>Cell reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2211-1247</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">36640300</article-id>
      <article-id pub-id-type="pmc">9972901</article-id>
      <article-id pub-id-type="doi">10.1016/j.celrep.2023.111990</article-id>
      <article-id pub-id-type="manuscript">NIHMS1872761</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A multiplexed in vivo approach to identify driver genes in small cell lung cancer</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Myung Chang</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cai</surname>
            <given-names>Hongchen</given-names>
          </name>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Murray</surname>
            <given-names>Christopher W.</given-names>
          </name>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Chuan</given-names>
          </name>
          <xref rid="A3" ref-type="aff">3</xref>
          <xref rid="A6" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shue</surname>
            <given-names>Yan Ting</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Andrejka</surname>
            <given-names>Laura</given-names>
          </name>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>He</surname>
            <given-names>Andy L.</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Holzem</surname>
            <given-names>Alessandra M.E.</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Drainas</surname>
            <given-names>Alexandros P.</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ko</surname>
            <given-names>Julie H.</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Coles</surname>
            <given-names>Garry L.</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kong</surname>
            <given-names>Christina</given-names>
          </name>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhu</surname>
            <given-names>Shirley</given-names>
          </name>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhu</surname>
            <given-names>ChunFang</given-names>
          </name>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Jason</given-names>
          </name>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van de Rijn</surname>
            <given-names>Matt</given-names>
          </name>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Petrov</surname>
            <given-names>Dmitri A.</given-names>
          </name>
          <xref rid="A3" ref-type="aff">3</xref>
          <xref rid="A5" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Winslow</surname>
            <given-names>Monte M.</given-names>
          </name>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A4" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sage</surname>
            <given-names>Julien</given-names>
          </name>
          <xref rid="A1" ref-type="aff">1</xref>
          <xref rid="A2" ref-type="aff">2</xref>
          <xref rid="A7" ref-type="aff">7</xref>
          <xref rid="CR1" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Pediatrics, Stanford University, 265 Campus Drive, SIM1 G2078, Stanford, CA 94305, USA</aff>
      <aff id="A2"><label>2</label>Department of Genetics, Stanford University, Stanford, CA 94305, USA</aff>
      <aff id="A3"><label>3</label>Department of Biology, Stanford University, Stanford, CA 94305, USA</aff>
      <aff id="A4"><label>4</label>Department of Pathology, Stanford University, Stanford, CA 94305, USA</aff>
      <aff id="A5"><label>5</label>Chan Zuckerberg Biohub, San Francisco, CA 94158, USA</aff>
      <aff id="A6"><label>6</label>Present address: Microsoft, Redmond, WA 98052, USA</aff>
      <aff id="A7"><label>7</label>Lead contact</aff>
      <author-notes>
        <corresp id="CR1"><label>*</label>Correspondence: <email>julsage@stanford.edu</email></corresp>
        <fn fn-type="con" id="FN1">
          <p id="P1">AUTHOR CONTRIBUTIONS</p>
          <p id="P2">M.C.L. and J.S. designed most of the experiments and interpreted the results, with help from M.M.W. M.C.L. performed most of the experiments and analysis. H.C., C.W.M., L.A., and M.M.W. helped design and generate Tuba-seq vectors, prepare Tuba-seq libraries from mouse lung, and design Tuba-seq experiments and interpret resulting data. C.L. performed the Tuba-seq analysis under supervision of D.A.P. Y.T.S., A.L.H., J.H.K., and G.L.C. helped perform naphthalene injection, virus instillation, and lung collection. A.M.E.H. and A.P.D. helped design, generate vectors for, and run the CyTOF for the epitope-tagged NCI-H82 competition assay. C.K. performed the histopathological analysis. S.Z., C.Z., and J.W. performed the laser-capture microdissection experiments under supervision of M.V.D.R. M.C.L. and J.S. wrote the manuscript with contributions from all authors.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>23</day>
        <month>2</month>
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>31</day>
        <month>1</month>
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>1</month>
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>28</day>
        <month>2</month>
        <year>2023</year>
      </pub-date>
      <volume>42</volume>
      <issue>1</issue>
      <fpage>111990</fpage>
      <lpage>111990</lpage>
      <permissions>
        <license>
          <ns0:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ns0:license_ref>
          <license-p>This is an open access article under the CC BY-NC-ND license (<ext-link ext-link-type="uri" ns1:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract id="ABS1">
        <title>SUMMARY</title>
        <p id="P3">Small cell lung cancer (SCLC) is a lethal form of lung cancer. Here, we develop a quantitative multiplexed approach on the basis of lentiviral barcoding with somatic CRISPR-Cas9-mediated genome editing to functionally investigate candidate regulators of tumor initiation and growth in genetically engineered mouse models of SCLC. We found that naphthalene pre-treatment enhances lentiviral vector-mediated SCLC initiation, enabling high multiplicity of tumor clones for analysis through high-throughput sequencing methods. Candidate drivers of SCLC identified from a meta-analysis across multiple human SCLC genomic datasets were tested using this approach, which defines both positive and detrimental impacts of inactivating 40 genes across candidate pathways on SCLC development. This analysis and subsequent validation in human SCLC cells establish TSC1 in the PI3K-AKT-mTOR pathway as a robust tumor suppressor in SCLC. This approach should illuminate drivers of SCLC, facilitate the development of precision therapies for defined SCLC genotypes, and identify therapeutic targets.</p>
      </abstract>
      <abstract id="ABS2" abstract-type="graphical">
        <title>Graphical Abstract</title>
        <p id="P4">
<graphic ns1:href="nihms-1872761-f0001.jpg" position="anchor" />
</p>
      </abstract>
      <abstract id="ABS3" abstract-type="summary">
        <title>In brief</title>
        <p id="P5">Lee et al. report a meta-analysis of published genomic studies to identify candidate drivers of SCLC development in patients. They implement a genetic screening approach in mouse models of SCLC to functionally validate mTOR signaling as a key driver of SCLC development, including the TSC1 tumor suppressor.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec id="S1">
      <title>INTRODUCTION</title>
      <p id="P6">Small cell lung cancer (SCLC) constitutes about 15% of all lung cancers and is one of the most aggressive forms of human cancer.<sup><xref rid="R1" ref-type="bibr">1</xref>-<xref rid="R3" ref-type="bibr">3</xref></sup> Mortality in SCLC remains high, with a median survival of 8&#8211;10 months, as SCLC tumors are highly metastatic and become rapidly resistant to therapeutic approaches.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> The malignancy of SCLC cells is at least in part encoded by the complexity of genomic alterations induced by cigarette smoking.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> A major goal in the field has been to identify genetic drivers of SCLC growth, with the intent of eventually mirroring the successes with targeted therapies achieved in lung adenocarcinoma.<sup><xref rid="R6" ref-type="bibr">6</xref></sup></p>
      <p id="P7">Inactivation of the <italic toggle="yes">TP53</italic> and <italic toggle="yes">RB1</italic> tumor suppressor genes is a near universal event in SCLC. Other recurrent alterations in SCLC genomes include inactivation of tumor suppressors such as NOTCH family members or the MLL2 chromatin remodeler, and amplification of oncogenes such as MYC family transcription factors.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> Because of the high tumor mutation burden (TMB) in SCLC cells, however, distinguishing driver alterations from passengers remains challenging. For instance, <italic toggle="yes">KMT2D</italic> (encoding MLL2) is among the largest genes (&gt;40 kb) in the human genome; consequently, mutations within this gene have not been classified as putative drivers in the largest published genomic analyses of SCLC.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> However, functional analyses strongly suggest that MLL2 loss is an important driver of SCLC.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup></p>
      <p id="P8">Genetically engineered mouse models of cancer provide a platform with which candidate cancer driver alterations can be functionally interrogated in a relevant <italic toggle="yes">in vivo</italic> context. The development of SCLC mouse models that recapitulate the inactivation of <italic toggle="yes">TP53</italic> and <italic toggle="yes">RB1</italic> in human SCLC has enabled the investigation of the role of additional candidate drivers of SCLC.<sup><xref rid="R10" ref-type="bibr">10</xref>-<xref rid="R12" ref-type="bibr">12</xref></sup> However, thus far, progress in functionally validating potential driver mutations has been slow, with only a limited number of genes being tested since the first mouse model of SCLC was developed close to 20 years ago.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R13" ref-type="bibr">13</xref>-<xref rid="R18" ref-type="bibr">18</xref></sup></p>
      <p id="P9">Almost all genetically engineered mouse models of SCLC entail tumor initiation via the delivery of the Cre recombinase by an adenoviral vector (Ad-Cre) to delete conditional mutant alleles of <italic toggle="yes">Rb1</italic> and <italic toggle="yes">Trp53</italic>.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R11" ref-type="bibr">11</xref>-<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> Notably, adenoviral vectors do not integrate into the DNA of the transduced cells. Although this may be beneficial in synchronizing the time of tumor initiation, it is unsuitable for experimental studies in which sustained transgene expression or genetic tagging of transduced cells is required. The recent development of Tuba-seq (tumor barcoding with ultradeep barcode sequencing) has enabled the functional investigation of pools of putative driver genes in a quantitative and scalable manner in mouse models of lung adenocarcinoma.<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> In this approach, each cell transduced by a lentiviral-Cre vector (Lenti-sgRNA/Cre) and its descendants are stably labeled with a clonal identifier in the form of a random DNA barcode (BC) as well as a vector-specific identifier to distinctly label each unique genetic perturbation (i.e., sgRNA-ID or sgID). Thus, the importance of each sgRNA-targeted gene during tumor initiation and growth can be studied quantitatively. Furthermore, the presence of sgID allows simultaneous testing of multiple sgRNAs in one mouse with a pool of multiple lentiviral vectors. Although the Tuba-seq pipeline is in theory generalizable to any <italic toggle="yes">in vivo</italic> model that is amenable to lentiviral transduction and relies upon a conditionally regulated tumorigenic program, it has not yet been applied to study the genetic underpinnings of SCLC development.</p>
      <p id="P10">Here we present a barcoded Lenti-Cre-based mouse model of SCLC, which allows tracking of SCLC tumor clones that develop entirely within the native environment. We show that pre-treatment with naphthalene is key to efficient initiation of SCLC using lentiviral vectors, which enables the analysis of many tumor genotypes with Tuba-seq. We quantitatively assessed the impact of 40 genes on the initiation and growth of SCLC in a minimal number of mice. Our work validates the PI3K-AKT-mTOR pathway as an important driver of SCLC development and demonstrates a key role for TSC1 in this pathway as a potent tumor suppressor in SCLC.</p>
    </sec>
    <sec id="S2">
      <title>RESULTS</title>
      <sec id="S3">
        <title>Naphthalene treatment enhances the development of SCLC in mice</title>
        <p id="P11"><italic toggle="yes">Rb1</italic><sup><italic toggle="yes">fl/fl</italic></sup>;<italic toggle="yes">Trp53</italic><sup><italic toggle="yes">fl/fl</italic></sup>;<italic toggle="yes">Rbl2</italic><sup><italic toggle="yes">fl/fl</italic></sup> (<italic toggle="yes">RPR2</italic> or TKO [triple knockout]) mice model the most prevalent subtype of human SCLC (SCLC-A, with high expression of ASCL1<sup><xref rid="R22" ref-type="bibr">22</xref></sup>). In this mouse model, tumor initiation is efficient and tumor progression relatively rapid (4&#8211;6 months) following intratracheal instillation with Ad-CMV-Cre.<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup> Although <italic toggle="yes">RPR2</italic>;<italic toggle="yes">R26</italic><sup><italic toggle="yes">LSL-tdTomato</italic></sup> (<italic toggle="yes">RPR2T</italic>) mice developed SCLC upon transduction with Lenti-Cre (HIV-PGK-Cre backbone) (<xref rid="F1" ref-type="fig">Figures 1A</xref>-<xref rid="F1" ref-type="fig">1C</xref>), the overall tumor numbers were much lower than in <italic toggle="yes">RPR2</italic> mutant mice using Ad-CMV-Cre despite similar titers (<xref rid="SD2" ref-type="supplementary-material">Table S1</xref>).<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Naphthalene is a compound that kills most club cells in the lung epithelium.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> On the basis of a previous report using naphthalene prior to lentiviral transduction to generate lung tumors in mice,<sup><xref rid="R25" ref-type="bibr">25</xref></sup> we injected <italic toggle="yes">RPR2T</italic> mice with either naphthalene or vehicle (corn oil) two days prior to intratracheal delivery of Lenti-Cre (<xref rid="F1" ref-type="fig">Figure 1A</xref>). Naphthalene pre-treatment significantly increased both tumor number and burden in this context (<xref rid="F1" ref-type="fig">Figures 1B</xref> and <xref rid="F1" ref-type="fig">1C</xref>). Importantly, Lenti-Cre-initiated tumors showed histopathological characteristics of SCLC-A tumors, including high expression of ASCL1 and the neuroendocrine marker UCHL1 (<xref rid="F1" ref-type="fig">Figures 1D</xref>, <xref rid="F1" ref-type="fig">1E</xref>, and <xref rid="SD1" ref-type="supplementary-material">S1A</xref>). Tumors initiated using a different Lenti-Cre vector backbone (FIV-CMV-Cre) showed similar SCLC-A histology (<xref rid="SD1" ref-type="supplementary-material">Figure S1B</xref>). In contrast to naphthalene pre-treatment, which increased tumor area also in the Ad-Cre model (<xref rid="SD1" ref-type="supplementary-material">Figures S1C</xref> and <xref rid="SD1" ref-type="supplementary-material">S1D</xref>), transduction with Ad-CMV-EGFP two days prior to Lenti-Cre transduction did not increase tumor number or area (<xref rid="SD1" ref-type="supplementary-material">Figures S1E</xref> and <xref rid="SD1" ref-type="supplementary-material">S1F</xref>), indicating that the pro-tumor effects of naphthalene are distinct from inflammatory responses upon adenoviral infection. Cell lines derived from <italic toggle="yes">RPR2T</italic> mutant tumors initiated by Ad-CMV-Cre or Lenti-Cre, with or without naphthalene treatment, formed floating clusters of cells in culture, similar to classical neuroendocrine SCLC cell lines (<xref rid="SD1" ref-type="supplementary-material">Figure S2A</xref>). Transcriptomic analysis confirmed expression of <italic toggle="yes">Ascl1</italic> and canonical neuroendocrine markers, with low levels of other transcription factors typical of other SCLC subtypes<sup><xref rid="R22" ref-type="bibr">22</xref></sup> (<xref rid="F1" ref-type="fig">Figures 1F</xref> and <xref rid="F1" ref-type="fig">1G</xref>).</p>
        <p id="P12">SCLC tumors in the Ad-CMV-Cre <italic toggle="yes">RPR2</italic> model can be initiated from cGRP<sup>+</sup> neuroendocrine lung epithelial cells (the minority of tumors) as well as from another, unknown non-neuroendocrine cell type(s) of origin.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> The presence of cells with non-neuroendocrine features (i.e., expressing the club cell marker CC10 or the NOTCH target HES1) within tumors initiated after naphthalene pre-treatment and Lenti-Cre transduction suggested that these tumors likely mostly originate from the same non-neuroendocrine cell type(s) as Ad-CMV-Cre SCLC tumors<sup><xref rid="R26" ref-type="bibr">26</xref></sup> (<xref rid="F1" ref-type="fig">Figures 1D</xref>, <xref rid="F1" ref-type="fig">1E</xref>, <xref rid="SD1" ref-type="supplementary-material">S2B</xref>, and <xref rid="SD1" ref-type="supplementary-material">S2C</xref>).</p>
        <p id="P13">Thus, naphthalene pre-treatment enhances SCLC development in the <italic toggle="yes">RPR2</italic> model. Given the potential ease with which this Lenti-Cre platform could be used to inactivate genes of interest using sgRNAs and the CRISPR-Cas9 system, we next moved on to identifying potential regulators of SCLC etiology for further study.</p>
      </sec>
      <sec id="S4">
        <title>A meta-analysis reveals both known and novel putative genetic regulators of SCLC</title>
        <p id="P14">To identify potential key drivers of SCLC pathogenesis, we performed a meta-analysis of 37 studies published prior to October 1, 2021, on human SCLC (<xref rid="F2" ref-type="fig">Figure 2A</xref>). We compiled data for not only genetic but also epigenetic and transcriptomic alterations in SCLC (<xref rid="SD2" ref-type="supplementary-material">Table S2</xref>). This analysis identified 3,285 potential driver gene candidates that were profiled in at least 250 patients, had an alteration frequency of &#8805;3%, and coded for proteins with amino acid residue lengths of &#8804;2,000 (<xref rid="SD2" ref-type="supplementary-material">Tables S3</xref> and <xref rid="SD2" ref-type="supplementary-material">S4</xref>). Whereas the relative rarity of SCLC tumor whole-genome/exome sequencing studies meant that many of the genes were examined in 400 patients or fewer, a number of the more highly profiled cancer-related genes benefited from larger coverage, with the total patient numbers ranging from 500 to about 2,000 (<xref rid="F2" ref-type="fig">Figure 2B</xref>). As expected, in this analysis, <italic toggle="yes">TP53</italic> and <italic toggle="yes">RB1</italic> ranked first and second, respectively, as the most frequently altered genes in SCLC (<xref rid="F2" ref-type="fig">Figure 2C</xref>). Although several top candidate genes identified in this meta-analysis, such as <italic toggle="yes">COL11A1</italic> and <italic toggle="yes">XPC</italic>, were previously identified to be recurrently mutated in SCLC or capable of initiating lung cancer upon inactivation,<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> others, such as <italic toggle="yes">HCN1, PCDH15</italic>, and <italic toggle="yes">ERICH3</italic>, have been studied minimally in cancer contexts and represent novel tumor suppressor gene candidates in SCLC (<xref rid="F2" ref-type="fig">Figure 2C</xref>). The 3,285 candidates were enriched in signaling and cancer-related pathways (<xref rid="F2" ref-type="fig">Figure 2D</xref>), including an enrichment in factors implicated in PI3K-AKT-mTOR signaling (<xref rid="F2" ref-type="fig">Figures 2D</xref>, <xref rid="SD1" ref-type="supplementary-material">S3A</xref>, <xref rid="SD1" ref-type="supplementary-material">S3B</xref>; <xref rid="SD2" ref-type="supplementary-material">Table S5</xref>). Furthermore, genes involved in DNA repair,<sup><xref rid="R29" ref-type="bibr">29</xref></sup> Notch signaling,<sup><xref rid="R5" ref-type="bibr">5</xref></sup> the WNT/Hippo-Merlin pathways,<sup><xref rid="R27" ref-type="bibr">27</xref></sup> and epigenetic and transcriptional regulation<sup><xref rid="R8" ref-type="bibr">8</xref></sup> showed high alteration rates (<xref rid="F2" ref-type="fig">Figure 2E</xref>).</p>
        <p id="P15">Overall, this meta-analysis identified several candidate tumor suppressor genes and cancer pathways, most of which have not been functionally validated in SCLC (<xref rid="SD2" ref-type="supplementary-material">Table S6</xref>).</p>
      </sec>
      <sec id="S5">
        <title>Quantitative <italic toggle="yes">in vivo</italic> CRISPR screening to test tumor-suppressive activity in SCLC</title>
        <p id="P16">To investigate gene candidates in the pathways identified in the meta-analysis in an <italic toggle="yes">in vivo</italic> model of SCLC, we combined the Lenti-Cre/naphthalene platform with tumor barcoding with ultradeep barcode sequencing, an approach initially developed to uncover cancer drivers in mouse models of lung adenocarcinoma.<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> We prioritized 40 genes from the 3,285 candidates identified in the meta-analysis, focusing on genes in key signaling pathways in SCLC (26 genes across pools 1&#8211;3; several of these genes are highlighted in <xref rid="F2" ref-type="fig">Figure 2E</xref>) and novel targets with high alteration rates in patients with SCLC (14 genes in pool 4; all candidate genes tested are marked boldface type in <xref rid="SD2" ref-type="supplementary-material">Table S6</xref>). We transduced <italic toggle="yes">RPR2T</italic>;<italic toggle="yes">H11</italic><sup><italic toggle="yes">LSL-Cas9</italic></sup> (<italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic>) mice with four independent Lenti-sg<italic toggle="yes">TSG</italic>/Cre pools consisting of Lenti/Cre expressing inert sgRNAs (as controls) and Lenti-sgRNA/Cre vectors targeting putative tumor suppressor genes (TSGs) chosen for further study from the meta-analysis (<xref rid="F3" ref-type="fig">Figure 3A</xref>). Lungs were harvested at different time points for the different pools to identify possible optimal times for analysis, with no clear difference observed between the time points (see below).</p>
        <p id="P17">Both <italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic> and control <italic toggle="yes">RPR2T</italic> mice showed robust tumor formation upon Cre delivery as evidenced by tdTomato fluorescence; <italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic> mice showed a trend toward increased lung weights suggestive of increased tumor burden upon loss of tumor suppressor genes (<xref rid="F3" ref-type="fig">Figures 3B</xref>, <xref rid="F3" ref-type="fig">3C</xref>, <xref rid="SD1" ref-type="supplementary-material">S4A</xref>, and <xref rid="SD1" ref-type="supplementary-material">S4B</xref>). To determine gene inactivation effects on SCLC initiation and progression, we isolated genomic DNA from bulk tumor-bearing lungs, PCR-amplified and sequenced the sgID-BC region in the Lenti-sgRNA/Cre vector, and analyzed the data. A previous study using <italic toggle="yes">RP</italic>;<italic toggle="yes">Pten</italic><sup><italic toggle="yes">fl/fl</italic></sup> conditional knockout mice showed that PTEN is a potent suppressor of SCLC development initiated by loss of p53 and RB.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> We found that inactivation of PTEN significantly increased tumor size and number in <italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic> mice, indicative of a potent tumor-suppressive role even with the additional inactivation of p130. Conversely, inactivation of the essential gene <italic toggle="yes">Pcna</italic> decreased tumor size and number, indicating that this pipeline has the ability to uncover both genotype-specific positive and negative effects on SCLC initiation and growth (<xref rid="F3" ref-type="fig">Figures 3D</xref> and <xref rid="F3" ref-type="fig">3E</xref>).<sup><xref rid="R30" ref-type="bibr">30</xref></sup> Distinct sgRNAs targeting the same gene consistently had similar effects in <italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic> mice (<xref rid="F3" ref-type="fig">Figures 3D</xref> and <xref rid="F3" ref-type="fig">3E</xref>). In contrast, sgRNAs targeting candidate cancer drivers had little to no effect on tumor growth in <italic toggle="yes">RPR2T</italic> mice lacking Cas9 (<xref rid="SD1" ref-type="supplementary-material">Figures S4C</xref> and <xref rid="SD1" ref-type="supplementary-material">S4D</xref>), as expected, indicating that sgID-BC enrichment and depletion recapitulate on-target gene inactivation activity. Quantifying tumor growth using alternative metrics showed similar results, with <italic toggle="yes">Pten</italic> and <italic toggle="yes">Tsc1</italic> inactivation increasing tumor burden and size and <italic toggle="yes">Arid1a</italic> and <italic toggle="yes">Pcna</italic> inactivation decreasing tumor burden in <italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic> mice, while sgRNAs had little to no effect in <italic toggle="yes">RPR2T</italic> mice (<xref rid="SD1" ref-type="supplementary-material">Figures S5A</xref>-<xref rid="SD1" ref-type="supplementary-material">S5D</xref>).</p>
        <p id="P18">This Tuba-seq analysis identified several new genetic modifiers of SCLC growth (<xref rid="F3" ref-type="fig">Figures 3D</xref> and <xref rid="F3" ref-type="fig">3E</xref>). First, <italic toggle="yes">Tsc1</italic> inactivation increased both tumor number and size, suggestive of a strong tumor suppressor role. Second, inactivation of <italic toggle="yes">Arid1a</italic> or <italic toggle="yes">Arid1b</italic> decreased tumor number and size in two independent pools, suggesting that ARID1A- and ARID1B-containing complexes normally promote rather than restrict the growth of SCLC in this genetic context. Third, inactivation of <italic toggle="yes">Nkx2-1</italic> led to increased tumor number but not size, suggesting a tumor-suppressive role for this lung lineage transcription factor at the time of tumor initiation. Finally, <italic toggle="yes">Kdm6a</italic> inactivation increased tumor number in pool 1, which was harvested at 14 weeks following tumor initiation, but showed a more modest effect in pool 2 collected at 21 weeks following tumor initiation, suggesting that KDM6A may be a more potent tumor suppressor in early lesions in this model.</p>
        <p id="P19">Taken together, these results indicate that adapting the Tuba-seq approach to an autochthonous murine model of SCLC enables identification of oncogenic drivers and tumor suppressors, and greatly increases throughput of <italic toggle="yes">in vivo</italic> analyses.</p>
      </sec>
      <sec id="S6">
        <title>Single-guide validation confirms TSC1 as a tumor suppressor in mouse SCLC</title>
        <p id="P20">Having observed frequent alterations in the PI3K-AKT-mTOR signaling pathway in our meta-analysis (<xref rid="F2" ref-type="fig">Figure 2E</xref>) and identified <italic toggle="yes">Tsc1</italic> as a potent tumor suppressor gene in the <italic toggle="yes">RPR2</italic> model using Tuba-seq (<xref rid="F3" ref-type="fig">Figures 3D</xref> and <xref rid="F3" ref-type="fig">3E</xref>), we further investigated the role of TSC1 in SCLC. In single-guide experiments, <italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic> mice transduced with low titers of Lenti-sg<italic toggle="yes">Tsc1</italic>/Cre vectors (to ensure visualization of individual tumors) (<xref rid="SD2" ref-type="supplementary-material">Table S1</xref>) developed both SCLC tumors and non-small cell lung cancer (NSCLC) tumors (giant cell lung adenocarcinoma) (<xref rid="F4" ref-type="fig">Figures 4A</xref>-<xref rid="F4" ref-type="fig">4C</xref>). Laser-capture microdissection followed by PCR amplification and sequencing of the sgID-BC in the Lenti-sgRNA/Cre vector showed that neighboring SCLC and NSCLC tumors arose from different clonal events (<xref rid="SD1" ref-type="supplementary-material">Figures S6A</xref>-<xref rid="SD1" ref-type="supplementary-material">S6C</xref>). Although PTEN, like TSC1, is a negative regulator of the PI3K-AKT-mTOR signaling pathway, <italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic> mice transduced with Lenti-sg<italic toggle="yes">Pten</italic>/Cre did not develop NSCLC tumors, unlike mice transduced with Lenti-sg<italic toggle="yes">Tsc1</italic>/Cre where 11 of 12 mice developed giant cell lung adenocarcinoma in addition to SCLC (<xref rid="SD1" ref-type="supplementary-material">Figures S7A</xref>-<xref rid="SD1" ref-type="supplementary-material">S7C</xref>). Although these <italic toggle="yes">Rb/p53/p130/Tsc1</italic> (<italic toggle="yes">RPR2</italic>;<italic toggle="yes">Tsc1</italic>) mutant tumors provide a new model for giant cell lung adenocarcinoma, we did not investigate their biology further. The neuroendocrine SCLC compartment in the <italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic> mice with <italic toggle="yes">Tsc1</italic> inactivation showed a trend toward increased tumor number and area compared with control <italic toggle="yes">RPR2T</italic> mice at this time point (<xref rid="F4" ref-type="fig">Figures 4B</xref> and <xref rid="F4" ref-type="fig">4C</xref>).</p>
        <p id="P21">A subset of the SCLC and NSCLC compartments had high levels of S6 phosphorylation compared with untransformed lung, suggesting elevated mTORC1 activity resulting from TSC1 inactivation (<xref rid="F4" ref-type="fig">Figure 4C</xref>). S6 phosphorylation was also increased in <italic toggle="yes">Tsc1</italic>-knockout (KO) SCLC cell lines (derived from <italic toggle="yes">RPR2</italic>;<italic toggle="yes">Tsc1</italic> tumors) compared with <italic toggle="yes">Tsc1</italic>-wild-type (WT) SCLC cell lines (<xref rid="F4" ref-type="fig">Figures 4D</xref>, <xref rid="F4" ref-type="fig">4E</xref>, <xref rid="SD1" ref-type="supplementary-material">S7D</xref>, and <xref rid="SD1" ref-type="supplementary-material">S7E</xref>). In addition, <italic toggle="yes">Tsc1</italic>-KO cell lines displayed significantly higher sensitivity to pharmacological mTOR inhibition using AZD8055 compared with <italic toggle="yes">Tsc1</italic>-WT SCLC cell lines (<xref rid="F4" ref-type="fig">Figure 4F</xref>). We further validated the tumor-suppressive function of TSC1 by re-expressing human TSC1 (hTSC1) in mouse tumor-derived cell lines via lentiviral transduction. Compared with the mouse SCLC cells expressing EGFP (as a control), SCLC cells (either wild-type or <italic toggle="yes">Tsc1</italic>-KO) ectopically expressing hTSC1 showed a significant decrease in their ability to expand in culture (<xref rid="F4" ref-type="fig">Figures 4G</xref>, <xref rid="SD1" ref-type="supplementary-material">S8A</xref>, and <xref rid="SD1" ref-type="supplementary-material">S8B</xref>).</p>
        <p id="P22">In the <italic toggle="yes">RP</italic> mouse model, Lenti-Cre initiates SCLC inefficiently even after naphthalene pre-treatment, with only 2&#8211;4 tumors visible at 42 weeks following transduction (<xref rid="SD1" ref-type="supplementary-material">Figures S9A</xref> and <xref rid="SD1" ref-type="supplementary-material">S9B</xref>). This small number of tumors and variable tumor development made quantification difficult and suggests that this mouse model may not be readily amenable to the Tuba-seq platform. <italic toggle="yes">RP</italic>;<italic toggle="yes">R26</italic><sup><italic toggle="yes">LSL-tdTomato</italic></sup>;<italic toggle="yes">H11</italic><sup><italic toggle="yes">LSL-Cas9</italic></sup> (<italic toggle="yes">RPT</italic>;<italic toggle="yes">Cas9</italic>) mice also developed giant cell lung adenocarcinoma following transduction with Lenti-sg<italic toggle="yes">Tsc1</italic>/Cre vector (<xref rid="SD1" ref-type="supplementary-material">Figures S9C</xref> and <xref rid="SD1" ref-type="supplementary-material">S9D</xref>), suggesting a broader role for TSC1 in regulating lung cancer development in different genetic contexts in mice.</p>
        <p id="P23">The <italic toggle="yes">RP</italic> and <italic toggle="yes">RPR2</italic> models represent the SCLC-A subtype. In contrast, <italic toggle="yes">Rb1</italic><sup><italic toggle="yes">fl/fl</italic></sup>;<italic toggle="yes">Trp53</italic><sup><italic toggle="yes">fl/fl</italic></sup>;<italic toggle="yes">H11</italic><sup><italic toggle="yes">LSL-MycT58A</italic></sup> (<italic toggle="yes">RPM</italic>) mice represent the MYC-overexpressing SCLC-N subtype (NEUROD1-high).<sup><xref rid="R7" ref-type="bibr">7</xref></sup> We generated <italic toggle="yes">RP</italic>;<italic toggle="yes">R26</italic><sup><italic toggle="yes">LSL-tdTomato/+</italic></sup>;<italic toggle="yes">H11</italic><sup><italic toggle="yes">LSL-MycT58A/LSL-Ca9</italic></sup> (<italic toggle="yes">RPMT</italic>;<italic toggle="yes">Cas9</italic>) mice and tested whether <italic toggle="yes">Tsc1</italic> acts as a tumor suppressor in this context also. As Lenti-Cre alone generates tumors in the <italic toggle="yes">RPM</italic> model in only 8 weeks, we transduced <italic toggle="yes">RPMT</italic>;<italic toggle="yes">Cas9</italic> mice without naphthalene pre-treatment (<xref rid="SD1" ref-type="supplementary-material">Figure S10A</xref>). Compared with <italic toggle="yes">RPMT</italic>;<italic toggle="yes">Cas9</italic> mice transduced with Lenti-sg<italic toggle="yes">Neo1</italic>/Cre (Lenti-sgInert/Cre), mice transduced with Lenti-sg<italic toggle="yes">Tsc1</italic>/Cre had increased tumor number and area (<xref rid="SD1" ref-type="supplementary-material">Figures S10A</xref>-<xref rid="SD1" ref-type="supplementary-material">S10C</xref>). Of note, although <italic toggle="yes">RPMT</italic>;<italic toggle="yes">Cas9</italic> mice transduced with Lenti-sgInert/Cre generated NEUROD1-high SCLC, as expected, there were areas of NSCLC histology in <italic toggle="yes">RPMT</italic>;<italic toggle="yes">Cas9</italic> mice transduced with Lenti-sg<italic toggle="yes">Tsc1</italic>/Cre, similar to our observations in the <italic toggle="yes">RPR2</italic> and <italic toggle="yes">RP</italic> models (<xref rid="F4" ref-type="fig">Figures 4A</xref> and <xref rid="SD1" ref-type="supplementary-material">S10D</xref>).</p>
        <p id="P24">In all, our results indicate that TSC1 is a tumor suppressor in both ASCL1-high and NEUROD1-high subtypes of SCLC and that <italic toggle="yes">Tsc1</italic> inactivation also induces NSCLC development in the <italic toggle="yes">RPR2, RP</italic>, and <italic toggle="yes">RPM</italic> genetic backgrounds.</p>
      </sec>
      <sec id="S7">
        <title>TSC1/TSC2 are tumor suppressors in human SCLC</title>
        <p id="P25">Following validation of <italic toggle="yes">Tsc1</italic> as a tumor suppressor gene in mouse models of SCLC, we next sought to validate the tumor-suppressive activity of TSC1 in human SCLC cells. We also investigated TSC2, the obligate partner of TSC1 within the tuberous sclerosis complex.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> We generated populations of NCI-H82 SCLC cells independently expressing six unique combinations of short epitopes (epitope-combinatorial-tag [EpicTag]<sup><xref rid="R32" ref-type="bibr">32</xref></sup>) and performed Cas9-RNA ribonucleoprotein nucleofection to generate <italic toggle="yes">TSC1</italic>-KO (in EpicTag 1 cells), <italic toggle="yes">TSC2</italic>-KO (in EpicTag 2 cells), and wild-type control cell lines (EpicTag 3&#8211;6 cells, which received non-targeting Cas9-sgRNA ribonucleoprotein) (<xref rid="F5" ref-type="fig">Figures 5A</xref> and <xref rid="SD1" ref-type="supplementary-material">S11A</xref>). We then pooled EpicTag 1~6 NCI-H82 cells, cultured them for 21 days, and measured the relative change in epitope-tag representation using cytometry by time of flight (CyTOF) (<xref rid="F5" ref-type="fig">Figure 5A</xref>). In this assay, <italic toggle="yes">TSC1</italic>-KO and <italic toggle="yes">TSC2</italic>-KO cells showed significantly increased expansion relative to the wild-type cell lines, making up the majority of the pool by day 21 (<xref rid="F5" ref-type="fig">Figures 5B</xref> and <xref rid="SD1" ref-type="supplementary-material">S11B</xref>). <italic toggle="yes">TSC1</italic>-KO and <italic toggle="yes">TSC2</italic>-KO cells also showed increased phosphorylated S6 compared with wild-type cell lines (<xref rid="F5" ref-type="fig">Figures 5C</xref> and <xref rid="SD1" ref-type="supplementary-material">S11C</xref>). In contrast to the development of NSCLC upon loss of <italic toggle="yes">Tsc1</italic> at the time of initiation in the mouse models, inactivation of <italic toggle="yes">TSC1</italic> or <italic toggle="yes">TSC2</italic> in NCI-H82 cells did not lead to any obvious fate change toward a non-neuroendocrine fate, with no differences observed in markers indicative of epithelial-to-mesenchymal transition (EMT) and non-neuroendocrine differentiation (<xref rid="SD1" ref-type="supplementary-material">Figure S11D</xref>). <italic toggle="yes">TSC1</italic>-WT and <italic toggle="yes">TSC1</italic>-KO NCI-H82 cell lines did not show significant differences in half maximal inhibitory concentration (IC<sub>50</sub>) values in response to the AZD8055 mTORC1/2 inhibitor (<xref rid="SD1" ref-type="supplementary-material">Figure S11E</xref>), suggesting that TSC1 inactivation at a later stage of tumor progression may not sensitize to mTOR inhibition.</p>
        <p id="P26">To further investigate TSC1 tumor-suppressive effects in SCLC, we profiled 9 human SCLC cell lines for their TSC1, TSC2, and phosphorylated S6 protein levels (<xref rid="F5" ref-type="fig">Figure 5D</xref>). Two cell lines, NCI-H1694 and NCI-H146, exhibited higher levels of phosphorylated S6 compared with other human SCLC; in particular, NCI-H146 showed lower expression of TSC1. We ectopically expressed hTSC1 or EGFP in these two cell lines alongside two other cell lines with low levels of S6 phosphorylation (NCI-H526 and NCI-H446) and monitored their growth (<xref rid="SD1" ref-type="supplementary-material">Figure S12A</xref>). Although the phosphorylation of mTOR pathway members did not change significantly following ectopic expression of hTSC1 under the conditions examined, hTSC1-expressing human SCLC cell lines nonetheless showed significantly slower growth compared with EGFP-expressing controls (<xref rid="F5" ref-type="fig">Figures 5E</xref> and <xref rid="SD1" ref-type="supplementary-material">S12B</xref>). Overall, these results validate TSC1 as a tumor suppressor in human SCLC.</p>
      </sec>
    </sec>
    <sec id="S8">
      <title>DISCUSSION</title>
      <p id="P27">In this study, we adapted a multiplexed and quantitative method to perform medium-throughput analysis of gene inactivation in mouse models of SCLC. Using this approach, we identified TSC1 as a potent tumor suppressor in SCLC. The implementation of the Tuba-seq platform to mouse models of SCLC will greatly accelerate the functional analysis of candidate drivers of SCLC initiation and growth <italic toggle="yes">in vivo</italic>.</p>
      <sec id="S9">
        <title>Multiplexed gene knockouts in mouse models to investigate candidate tumor suppressors and genetic heterogeneity in SCLC</title>
        <p id="P28">Lentiviral barcoding approaches have enabled breakthroughs in understanding tumor heterogeneity, clonal evolution, and multiplexed gene perturbation effects.<sup><xref rid="R33" ref-type="bibr">33</xref>-<xref rid="R35" ref-type="bibr">35</xref></sup> In this study, we show that several advantages of lentiviral barcoding (e.g., multiplexed CRISPR screening and clonality analysis using barcoding approaches) can be captured in an autochthonous, <italic toggle="yes">in vivo</italic> context to study SCLC development. The application of Tuba-seq to mouse models of SCLC allowed us to investigate the gene perturbation effects at a much faster rate than previously capable. However, the lack of histological information (as exemplified with <italic toggle="yes">Tsc1</italic> loss and the appearance of a giant cell carcinoma phenotype) and necessity for single-guide validation remain limitations of this approach. Nonetheless, the cost and time savings from using this approach to identify SCLC drivers cannot be overstated, and future approaches could take advantage of the lentiviral barcoding further, tracking metastasis drivers and dissecting tumor clonal evolution, for instance.</p>
        <p id="P29">Although the MSK-IMPACT panel remains a major resource for cancer genomics, including SCLC, its focus on readily actionable cancer targets (341&#8211;468 genes) is a limitation.<sup><xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R37" ref-type="bibr">37</xref></sup> We sought to supplement and extend the currently available dataset in our meta-analysis from 37 different studies by adding more whole-genome/whole-exome sequencing studies in addition to studies profiling specific sets of genes. Because we aggregated our datasets for the sake of simplicity rather than keeping the individual patient IDs intact (i.e., keeping only the total number of patients with a given alteration in a gene), the cBioPortal remains a distinct resource for examining mutual exclusivity and co-occurrence patterns. Nonetheless, our meta-analysis database simplifies the search for novel cancer drivers by organizing aggregated patient alteration data alongside other useful metrics such as protein information for coding genes, RNA sequencing (RNA-seq) expression datasets, and dependency scores from the Cancer Dependency Map (DepMap) project.</p>
        <p id="P30">Increasing evidence from human tumor sections and mouse models indicates that intra-tumoral heterogeneity on the basis of epigenetic/transcriptional program in SCLC cells plays a significant role in the growth of SCLC tumors and their response to treatment.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R38" ref-type="bibr">38</xref>-<xref rid="R41" ref-type="bibr">41</xref></sup> In contrast, our understanding of the genetic determinants of SCLC development has been hampered by limited tumor samples and the complex genome of these tumors. The development of medium-throughput pre-clinical approaches such as described here will contribute to a more rapid functional validation of genes and pathways relevant to SCLC in the clinic. A future goal of the field will be to explore how epigenetic and genetic mechanisms together mold SCLC development and response to various therapies to identify more personalized treatment strategies.</p>
      </sec>
      <sec id="S10">
        <title>The TSC1/2-mTOR pathway in SCLC</title>
        <p id="P31"><italic toggle="yes">TSC1</italic>, alongside its complex partner <italic toggle="yes">TSC2</italic>, was first identified as a key gene whose mutation causes tuberous sclerosis complex (TSC).<sup><xref rid="R42" ref-type="bibr">42</xref></sup> TSC patients present with several clinical features, including skin lesions, hamartomas, and subependymal giant cell tumor of the brain.<sup><xref rid="R42" ref-type="bibr">42</xref></sup> The development of tumors in TSC patients, particularly giant cell tumors, is thought to stem from TSC1-TSC2 complex&#8217;s role as a negative regulator of the mTOR pathway, which controls multiple pathways including cell growth.<sup><xref rid="R43" ref-type="bibr">43</xref>-<xref rid="R45" ref-type="bibr">45</xref></sup> We observed mTORCI activation and development of giant cell carcinoma of the lung upon <italic toggle="yes">Tsc1</italic> inactivation in our mouse models of SCLC. In a recent preprint describing 3,600 SCLC tumor specimens analyzed for genomic alterations in ~300 cancer genes, ~1.5% and 0.7% of patients displayed alterations in <italic toggle="yes">TSC1</italic> and <italic toggle="yes">TSC2</italic>, respectively.<sup><xref rid="R46" ref-type="bibr">46</xref></sup> As we did not examine events such as silencing due to methylation or complex chromosomal rearrangements, it is possible that these percentages underestimate the prevalence of <italic toggle="yes">TSC1/TSC2</italic> alteration in SCLC patients. Although only about 3%&#8211;4% of SCLC patients have <italic toggle="yes">TSC1</italic> alterations according to our meta-analysis, a substantial fraction of SCLC patients possess PI3K-AKT-mTOR pathway alterations (e.g., 9%&#8211;10% patients with <italic toggle="yes">TSC2</italic> alterations, 11%&#8211;12% with <italic toggle="yes">PTEN</italic> alterations). Although cases of combined SCLC/giant cell carcinoma of the lung are rare in the clinic,<sup><xref rid="R47" ref-type="bibr">47</xref>,<xref rid="R48" ref-type="bibr">48</xref></sup> our data suggest that these tumors may arise from dysregulation of the TSC1/TSC2-mTOR axis alongside RB/p53 loss of function.</p>
        <p id="P32">Our data in mice and human cells show the strong tumor-suppressive role of TSC1 in SCLC, as suggested by previous <italic toggle="yes">in vitro</italic> CRISPR-Cas9 knockout screens in mouse SCLC cell lines.<sup><xref rid="R49" ref-type="bibr">49</xref></sup> Several recent pre-clinical studies using SCLC models have also indicated that mTOR inhibition could be a viable strategy to treat SCLC patients, especially those resistant to chemotherapy. Although rapamycin analogs (e.g., temsirolimus and RAD001), which preferentially inhibit mTORC1 rather than mTORC2, were met with little success in phase II clinical trials,<sup><xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R51" ref-type="bibr">51</xref></sup> ATP-competitive mTOR inhibitors (e.g., AZD8055), which inhibit both mTORC1 and mTORC2, may be more promising. mTOR inhibition using AZD8055 led to decreased tumor growth and sensitization to cisplatin/etoposide therapy in a subset of patient-derived xenograft models,<sup><xref rid="R52" ref-type="bibr">52</xref></sup> and RICTOR amplification, which occurs in 10%&#8211;15% of SCLC patients, was also shown to predict response to mTOR inhibitors in SCLC cell lines.<sup><xref rid="R53" ref-type="bibr">53</xref></sup> Data from our study with mouse cell lines further suggest that AZD8055 may produce greater therapeutic benefit for patients whose tumors lost TSC1 function early in the course of their disease. Furthermore, mTOR inhibition rescued the efficacy of Bcl-2 inhibition as well as WEE1 inhibition in <italic toggle="yes">in vivo</italic> models of SCLC,<sup><xref rid="R54" ref-type="bibr">54</xref>,<xref rid="R55" ref-type="bibr">55</xref></sup> leading to an ongoing phase I/II clinical trial (<ext-link ns1:href="https://clinicaltrials.gov/ct2/show/NCT03366103" ext-link-type="uri">NCT03366103</ext-link>). Taken together with our data, these results suggest that ATP-competitive mTOR inhibitors may produce therapeutic benefit in patients with alterations in the PI3K-AKT-TSC1/2-mTOR axis.</p>
      </sec>
      <sec id="S11">
        <title>Limitations of the study</title>
        <p id="P33">Aside from <italic toggle="yes">TSC1</italic>, most of the driver gene candidates tested in this study did not score significantly in the Tuba-seq analysis. Although it is possible that the non-scoring genes are truly passengers, three other possible explanations exist for the high prevalence of non-scoring genes: (1) the loss of <italic toggle="yes">Rbl2</italic> in the <italic toggle="yes">RPR2</italic> model is already such a strong tumor-suppressive event that it masks the tumor growth effects of knocking out other tumor suppressor genes; (2) alterations in some genes/pathways are strong drivers of SCLC development (e.g., loss of RB, loss of p53, activation of the MYC family, alterations in the PTEN pathway), whereas others have more minor roles that our approach did not detect at the time point examined; and (3) some alterations may play a larger (or different) role during tumor progression rather than tumor initiation. ARID1A, for example, has been shown to play a context-dependent role in liver cancer, where homozygous loss at initiation protected against HCC initiation but loss following initiation accelerated tumor growth and metastasis.<sup><xref rid="R56" ref-type="bibr">56</xref></sup> Because our model possesses CRISPR-Cas9 activity at tumor initiation, the decrease in tumor size and number with sgRNAs against <italic toggle="yes">Arid1a</italic> and <italic toggle="yes">Arid1b</italic> is suggestive of a similar necessity for BAF complex activity at SCLC initiation and not necessarily indicative of their activity during progression. This difficulty in uncoupling the effect of gene inactivation at initiation with its role at progression may limit our interpretation of the roles that non-scoring candidate drivers may play in SCLC progression. Future studies, including investigating additional time points during cancer progression, are needed to uncover whether ARID1A/ARID1B and any of the non-scoring proposed candidate drivers show context-dependent or more nuanced roles in SCLC initiation and progression.</p>
      </sec>
    </sec>
    <sec id="S12">
      <title>STAR&#9733;METHODS</title>
      <sec id="S13">
        <title>RESOURCE AVAILABILITY</title>
        <sec id="S14">
          <title>Lead contact</title>
          <p id="P34">Further information and requests for resources and reagents should be directed to and will be fulfilled by lead contact, Julien Sage (<email>julsage@stanford.edu</email>).</p>
        </sec>
        <sec id="S15">
          <title>Materials availability</title>
          <p id="P35">Plasmids generated in this study have been deposited to Addgene (plasmids #193198&#8211;193249).</p>
        </sec>
        <sec sec-type="data-availability" id="S16">
          <title>Data and code availability</title>
          <p id="P36">RNA-seq, LCM sequencing, and Tuba-seq data are available through Gene Expression Omnibus (GEO: GSE198637). CyTOF data is available through Cytobank Community: #103066. Gene dependency data from the Cancer Dependency Map are publicly available at <ext-link ns1:href="http://www.depmap.org" ext-link-type="uri">www.depmap.org</ext-link>. Protein data from UniProtKB are publicly available at <ext-link ns1:href="http://www.uniprot.org" ext-link-type="uri">www.uniprot.org</ext-link>. Original, raw data and images have been deposited at Mendeley and are publicly available (Mendeley Data: <ext-link ns1:href="10.17632/nr4ssx645r.12" ext-link-type="doi">https://doi.org/10.17632/nr4ssx645r.12</ext-link>). All original code used to analyze data and generate figures are available at GitHub: <ext-link ns1:href="https://github.com/noahlee577/SCLC_Tuba-seq" ext-link-type="uri">https://github.com/noahlee577/SCLC_Tuba-seq</ext-link> (release v1.0.0 is archived at Zenodo: <ext-link ns1:href="10.5281/zenodo.7430243" ext-link-type="doi">https://doi.org/10.5281/zenodo.7430243</ext-link>). All other data are available in the <xref rid="SD1" ref-type="supplementary-material">Supplementary Information</xref>, or from the corresponding author upon reasonable request. Any additional information required to re-analyze the data reported in this work is available from the lead contact upon request.</p>
        </sec>
      </sec>
      <sec id="S17">
        <title>EXPERIMENTAL MODEL AND SUBJECT DETAILS</title>
        <sec id="S18">
          <title>Ethics statement</title>
          <p id="P37">Mouse maintenance and experiments were conducted in accordance with practices prescribed by the NIH, the Institutional Animal Care and Use Committee (IACUC), and Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). The study protocol was approved by the Administrative Panel on Laboratory Animal Care (APLAC) at Stanford University (protocol #APLAC-13565).</p>
        </sec>
        <sec id="S19">
          <title>Mice and tumor initiation</title>
          <p id="P38"><italic toggle="yes">Rb1</italic><sup><italic toggle="yes">fl/fl</italic></sup>;<italic toggle="yes">Trp53</italic><sup><italic toggle="yes">fl/fl</italic></sup>;<italic toggle="yes">Rbl2</italic><sup><italic toggle="yes">fl/fl</italic></sup> (<italic toggle="yes">RPR2</italic>) mice has been described previously.<sup><xref rid="R11" ref-type="bibr">11</xref></sup>
<italic toggle="yes">RPR2</italic> mice were crossed with <italic toggle="yes">Kras<sup>LSL-G12D/+</sup></italic>;<italic toggle="yes">Trp53<sup>fl/fl</sup></italic>;<italic toggle="yes">R26</italic><sup><italic toggle="yes">LSL-tdTomato/LSL-tdTomato</italic></sup>;<italic toggle="yes">H11</italic><sup><italic toggle="yes">LSL-Cas9/LSL-Cas9</italic></sup> (<italic toggle="yes">KPTC</italic>) mice to generate <italic toggle="yes">RPR2</italic>;<italic toggle="yes">R26</italic><sup><italic toggle="yes">LSL-tdTomato/LSL-tdTomato</italic></sup>;<italic toggle="yes">H11</italic><sup><italic toggle="yes">LSL-Cas9/LSL-Cas9</italic></sup> (<italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic>) and <italic toggle="yes">RPR2</italic>;<italic toggle="yes">R26</italic><sup><italic toggle="yes">LSL-tdTomato/LSL-tdTomato</italic></sup> (<italic toggle="yes">RPR2T</italic>) mice. <italic toggle="yes">Rb1</italic><sup><italic toggle="yes">fl/fl</italic></sup>;<italic toggle="yes">Trp53</italic><sup><italic toggle="yes">fl/fl</italic></sup>;<italic toggle="yes">R26</italic><sup><italic toggle="yes">LSL-tdTomato/+</italic></sup>;<italic toggle="yes">H11</italic><sup><italic toggle="yes">LSL-MycT58A/LSL-Cas9</italic></sup> (<italic toggle="yes">RPMT</italic>;<italic toggle="yes">Cas9</italic>) mice were generated by crossing <italic toggle="yes">Rb1</italic><sup><italic toggle="yes">fl/fl</italic></sup>;<italic toggle="yes">Trp53</italic><sup><italic toggle="yes">fl/fl</italic></sup>;<italic toggle="yes">H11</italic><sup><italic toggle="yes">LSL-MycT58A/LSL-MycT58A</italic></sup> (<italic toggle="yes">RPM</italic>) mice with <italic toggle="yes">Rb1</italic><sup><italic toggle="yes">fl/fl</italic></sup>;<italic toggle="yes">Trp53</italic><sup><italic toggle="yes">fl/fl</italic></sup>;<italic toggle="yes">R26</italic><sup><italic toggle="yes">LSL-tdTomato/LSL-tdTomato</italic></sup>;<italic toggle="yes">H11</italic>
<sup><italic toggle="yes">LSL-Cas9/LSL-Cas9</italic></sup> (<italic toggle="yes">RPT</italic>;<italic toggle="yes">Cas9</italic>) mice. 8- to 12-weeks-old mice were instilled with Lenti-sgRNA/Cre viruses via intratracheal delivery to generate lung tumors as previously described.<sup><xref rid="R68" ref-type="bibr">68</xref></sup> Both male and female mice were used in this study. Viral titers used for experiments are detailed in <xref rid="SD2" ref-type="supplementary-material">Table S1</xref>. Ad5-CMV-Cre (Ad-Cre) and FIV-CMV-Cre (Lenti-Cre) were supplied by University of Iowa Viral Vector Core (VVC-U of Iowa-5 and VVC-U of Iowa-28).</p>
          <p id="P39">Naphthalene (Sigma-Aldrich 184500) was dissolved into corn oil vehicle (Sigma-Aldrich C8267) at a concentration of 50 mg/mL and administered to mice via intraperitoneal (i.p.) injections at a dosage of 200 mg/kg.</p>
        </sec>
        <sec id="S20">
          <title>Cell line models</title>
          <p id="P40">Human SCLC cell lines (NCI-H1694, ATCC CRL-5888; NCI-H146, ATCC HTB-173; NCI-H2227, CRL-5934; NCI-H1876, CRL-5902; NCI-H889, CRL-5817; NCI-H526, CRL-5811; NCI-H2081, CRL-5920; NCI-H446, HTB-171; NCI-H524, CRL-5831; and NCI-H82, ATCC HTB-175) and mouse SCLC cell lines (KP11, described in,<sup><xref rid="R57" ref-type="bibr">57</xref></sup> KP22, 12N1G, and N2N1G, described in<sup><xref rid="R15" ref-type="bibr">15</xref></sup>) were cultured in RPMI 1640 media (Corning 15-040-CV) supplemented with 10% bovine growth serum (BGS, Thermo Fisher Scientific SH3054103HI) and 1% Penicillin-Streptomycin-Glutamine (Gibco 10378&#8211;016). 293T cells used for lentiviral preparation were cultured in Dulbecco&#8217;s Modified Eagle Medium (DMEM) High-Glucose medium (Gibco 11965&#8211;118) supplemented with 10% fetal bovine serum (Omega Scientific FB-01). All cell lines were confirmed to be negative for mycoplasma (MycoAlert Detection Kit, Lonza LT07-418).</p>
          <p id="P41">New mouse tumor-derived cell lines are described in <xref rid="SD2" ref-type="supplementary-material">Table S7</xref>. Briefly, tumor samples were microdissected and minced using a razor blade, digested with trypsin at 37&#176;C for 5 minutes, quenched with RPMI media containing bovine growth serum (BGS), and centrifuged at 1000 RPM for 5 minutes to remove the supernatant. The pellet was resuspended in RPMI media, filtered through 40 &#956;m membrane, and cultured at 37&#176;C. Resulting tumor spheroids were checked for tdTomato fluorescence using Leica fluorescence microscope and imaged with LAS X software (v3.7.1, Leica Microsystems, Wetzlar, Germany). <italic toggle="yes">In vitro</italic> fluorescence images were pseudo-colored using Fiji (v1.53f51).<sup><xref rid="R63" ref-type="bibr">63</xref></sup></p>
        </sec>
      </sec>
      <sec id="S21">
        <title>METHOD DETAILS</title>
        <sec id="S22">
          <title>Drug sensitivity and growth curve assays</title>
          <p id="P42">For the drug sensitivity assays, cells were plated at a density of 10K cells per well in 100 &#956;L media in 96-well plates on Day 0. On Day 1, 100 &#956;L RPMI media containing 2X concentration of AZD8055 (Selleckchem S1555) were added to wells, and 20 &#956;L of alamarBlue<sup>&#8482;</sup> Cell Viability Reagent (Invitrogen DAL1100) was added to the wells on Day 4. Well fluorescence (530 nm excitation, 590 nm emission) was measured following 5 &#8211; 6 h of incubation at 37&#176;C.</p>
          <p id="P43">For EGFP- or hTSC1-expressing mouse and human SCLC cell lines, cell lines were transduced with lentiviral vectors (see below), selected with 16 &#956;M blasticidin (Gibco A1113903) after 1&#8211;2 days, and plated for experiments 5 days following blasticidin selection, confirmation of EGFP fluorescence in EGFP-expressing lines, and &lt;1% viability in un-transduced control cell lines with trypan blue cell counting. For growth curve experiments, cells were plated at a density of 100K cells in 1 mL RPMI media per well in a 6-well plate on Day 0. Cells were imaged using Leica fluorescence microscope controlled via LAS X software (v3.7.1, Leica Microsystems, Wetzlar, Germany). As with mouse tumor-derived cell lines, <italic toggle="yes">in vitro</italic> fluorescence images were pseudo-colored using Fiji (v1.53f51).<sup><xref rid="R63" ref-type="bibr">63</xref></sup></p>
        </sec>
        <sec id="S23">
          <title>Ribonucleoprotein nucleofection with Cas9</title>
          <p id="P44">Control and targeting sgRNAs were generated as previously described.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> Briefly, for each region of interest, three sgRNAs were designed to hybridize approximately 150 bases apart, and 100 pmol of each sgRNA was resuspended in Tris-EDTA (Synthego) and mixed at a 1:1:1 ratio. In a 96-well v-bottom plate, 3 &#956;L of the sgRNA (total 300 pmol) was added to 12 &#956;L of SE buffer (Lonza V4XC-1032). In another well, 0.5 &#956;L of Alt-R<sup>&#174;</sup> S.p. Cas9 (Integrated DNA Technologies 1081059) was added to 10 &#956;L of SE buffer, and the Cas9 mix was added to the sgRNA solution, mixed thoroughly, and incubated at 37&#176;C for 15 minutes to form the RNP solution. 1 &#215; 10<sup>6</sup> NCI-H82 cells were resuspended in 5 &#956;L of SE Buffer, and cells were nucleofected with Lonza 4D-Nucleofector<sup>&#8482;</sup> X Unit (Lonza AAF-1002X) with the EN150 program immediately following addition of the RNP solution. Following the nucleofection, warm RPMI media was added to the cells, and cells were incubated at 37&#176;C for 15 minutes then transferred to a 24-well plate.</p>
        </sec>
        <sec id="S24">
          <title>Cell preparation for CyTOF</title>
          <p id="P45">Frozen cell lines in RPMI media supplemented with 10% BGS and 10% DMSO (Fisher Scientific BP231) were thawed, and 3 million cells per sample were washed once with PBS. The cells were then fixed with 1.6% formaldehyde at room temperature for 20 minutes. We are using palladium (Pd) barcoding to pool up to 20 different samples and reduce tube-to-tube variability. Therefore, cells were washed twice with PBS before permeabilization with PBS and 0.02% Saponin (Sigma-Aldrich 84510) at 4&#176;C. 11 &#956;L of Pd barcode was added to 1 mL of PBS and 0.02% Saponin, of which 900 &#956;L were used to resuspend each sample. This mix was incubated at room temperature for 15 min, washed three times with Cell Staining Media (CSM, PBS with 0.5% BSA (Thermo Fisher Scientific B14), 0.02% NaN<sub>3</sub> (Fisher Scientific MP210289110)), and then pooled into a single tube for staining with metal-labeled antibodies (<xref rid="SD2" ref-type="supplementary-material">Table S8</xref>) for 1 hour at room temperature. Antibodies against Flag, mCherry, GFP, VSV, NWS, Prot C, Ha, AU1, Synaptophysin, Vimentin, S6, GMNN, EZH2, pYAP, CDT1, pI3K, HES1 were conjugated with MAXPAR X8 Multimetal Labeling Kit (Fluidigm 201300) according to the manufacturer&#8217;s protocol. Antibodies were diluted to 0.2 &#956;g/mL and titered. Cells were stained with a range of 1:100 to 1:200 with each of the different antibodies in a staining volume of 150 &#956;L (~3 &#215; 10<sup>6</sup> cells/mL). After antibody staining, the cells were washed twice with CSM and then incubated overnight at 4&#176;C with an iridium-containing intercalator (Fluidigm 201192B) in PBS with 1.6% formaldehyde. The cells were then washed twice with water, diluted with water and 10 &#956;L/mL EU Four Element Calibration Beads (Fluidigm 201078) to ~10<sup>6</sup> cells/mL, and filtered through a 70-&#956;m membrane (Falcon 352350) just before analysis by mass cytometry.</p>
        </sec>
        <sec id="S25">
          <title>Lentiviral vector generation and titering</title>
          <p id="P46">Lentiviral vectors containing individual sgRNAs, barcode sequences, and Cre recombinase were generated as previously described, using unbarcoded Lenti-U6-sgNeo1/PGK-Cre vector as the template.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> Briefly, sgRNA sequences were picked based on an aggregated score from top hits on Desktop Genetics (formerly <ext-link ns1:href="http://www.deskgen.com" ext-link-type="uri">www.deskgen.com</ext-link>) and GPP sgRNA Designer offered by the Broad Institute (<ext-link ns1:href="https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design" ext-link-type="uri">https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design</ext-link>). Several of the sgRNAs used have been validated in previous studies.<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R59" ref-type="bibr">59</xref>-<xref rid="R62" ref-type="bibr">62</xref></sup> Detailed sgRNA and barcoding primer sequence information can be found in <xref rid="SD2" ref-type="supplementary-material">Table S9</xref>. Lenti-sgRNA/Cre plasmids were barcoded individually with an 8-nucleotide ID specific to each sgRNA (sgID) and 20-nucleotide random barcode sequence (BC), and each plasmid was packaged separately in 293T cells via co-transfection with polyethylenimine alongside pCMV-VSV-G (Addgene #8454) envelope plasmid and pCMV-dR8.2 dvpr (Addgene #8455) packaging plasmid.<sup><xref rid="R58" ref-type="bibr">58</xref></sup> Sodium butyrate (Sigma-Aldrich B5587-5G) was added eight hours following the transfection to increase viral titer. Viral supernatant was collected at 48 and 60 hour time points following transfection, filtered using 0.45 &#956;m PES syringe filter (Millipore SLHP033RB), concentrated via ultracentrifugation at 25,000 RPM for 90 minutes at 4&#176;C, resuspended in PBS overnight, and titered using LSL-YFP mouse embryonic fibroblasts (MEFs) as previously described.<sup><xref rid="R20" ref-type="bibr">20</xref></sup></p>
          <p id="P47">For the hTSC1 expression experiments, VectorBuilder was contracted to generate Lenti-EFS-EGFP-T2A-Bsd (Addgene #193198) and Lenti-EFS-hTSC1-T2A-Bsd (Addgene #193199) plasmids. Plasmids were co-transfected and packaged in the same way as the Lenti-sgRNA/Cre plasmids, with some differences: 1) sodium butyrate was not added and 2) the viral supernatant was collected at a 72-hour time point and added directly to the cells to be transduced after being filtered using 0.45 &#956;m PES syringe filter.</p>
        </sec>
        <sec id="S26">
          <title>Histology, immunohistochemistry, and immunofluorescence</title>
          <p id="P48">Mouse tissues were dissected from animals immediately following euthanasia. Lungs were inflated with 10% neutral buffered formalin (NBF), and all tissues were fixed in 10% NBF overnight following a brief rinse in PBS. Tissues were transferred to 70% ethanol prior to paraffin embedding and processing.</p>
          <p id="P49">Prior to immunohistochemistry, paraffin sections were rehydrated by 5-minute serial immersion in Histo-Clear, 100% ethanol, 95% ethanol, 70% ethanol, and water. Antigen retrieval was performed by immersing rehydrated slides in citrate-based antigen unmasking solution (H-3300, Vector Laboratories) at boiling temperature for 15 minutes. To block endogenous peroxidase activity, the slides were then incubated in 3% hydrogen peroxide for 1 hour. Slides were washed in PBS-T (PBS +0.1% Tween-20), blocked using blocking buffer (5% horse serum in PBS-T) for 1 hour at room temperature, and incubated with primary antibodies at 4&#176;C overnight. Following incubation, slides were washed in PBS-T, incubated with the secondary antibody for 1 hour at room temperature, and developed using DAB reagent (Vector Laboratories SK-4100) following another series of PBS-T washes. For HES1, ImmPRESS<sup>&#174;</sup> Excel Amplified Polymer Staining Kit, Anti-Rabbit IgG, Peroxidase (Vector Laboratories MP-7601) or TSA Plus Fluorescein kit (Akoya Biosciences NEL741001KT) were used to amplify signal for immunohistochemistry or immunofluorescence, respectively. Following development, slides were counterstained using hematoxylin (Sigma-Aldrich HHS32), dehydrated by 5-minute serial immersions in 70% ethanol, 100% ethanol and xylene, and mounted with Refrax Mounting Medium (Anatech Ltd 711).</p>
          <p id="P50">For immunofluorescence, all the same steps as immunohistochemistry were followed until the secondary antibody step; slides were incubated with fluorescent secondary antibodies diluted in blocking buffer (5% horse serum in PBS-T) for 1 hour, washed in PBS-T, and stained with 0.6 nM DAPI in PBS for 10 minutes at room temperature. Slides were mounted with Fluoromount-G (SouthernBiotech 0100&#8211;01) and stored in 4&#176;C overnight or &#8722;20&#176;C for a few days before visualization.</p>
          <p id="P51">The following antibodies were used for immunohistochemistry and immunofluorescence: ImmPRESS HRP Horse anti-Rabbit IgG (Vector Laboratories MP-7801-15), ImmPRESS HRP Horse anti-Mouse IgG (Vector Laboratories MP-7802-15), Alexa Fluor 594 Donkey anti-Goat IgG (H + L) Cross-Adsorbed Secondary Antibody (Invitrogen A11058), Alexa Fluor 488 Donkey anti-Rabbit IgG (H + L) Highly Cross-Adsorbed Secondary Antibody (Invitrogen A-21206), anti-RFP (for immunohistochemistry, Rockland 600-401-379, 1:200), anti-RFP (for immunofluorescence, MyBioSource MBS448122, 1:200), anti-CC10 (E&#8211;11, Santa Cruz sc-365992, 1:200), anti-HES1 (D6P2U, CST 11988S, 1:200), anti-NEUROD1 (Abcam ab109224, 1:200), anti-UCHL1 (Sigma-Aldrich HPA005993, 1:2,500), anti-phospho-S6 (Ser235/236, CST 2211, 1:200), and anti-MASH1 (BD Biosciences 556604, 1:200).</p>
        </sec>
        <sec id="S27">
          <title>Quantitative immunoassay analysis</title>
          <p id="P52">Cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, 1% NP40, 2 mM EDTA, 100 mM NaCl) supplemented with cOmplete<sup>&#8482;</sup> ULTRA Protease Inhibitor Cocktail tablets (Roche 5892970001) and PhosSTOP<sup>&#8482;</sup> phosphatase inhibitor tablets (Roche 4906845001). Pierce BCA Protein Assay Kit was used to quantify total protein concentration (Thermo Fisher Scientific 23227). For quantitative immunoassays, Simple Western<sup>&#8482;</sup> assay was performed on the Wes<sup>&#8482;</sup> system (ProteinSimple) according to manufacturer&#8217;s protocol, with 1 &#956;g of protein loaded per lane. Primary antibodies against the protein of interest and a loading control protein were run simultaneously in each lane. Compass for SW (v5.0.1, SimpleWestern) software was used for protein quantification and size determination. The authors note that the protein sizes tend to run larger on the Wes system compared to traditional immunoblotting. The following antibodies were used: anti-HSP90 (CST 4877, 1:4,000), anti-TSC1 (D43E2, CST 6935, 1:200), anti-TSC2 (D93F12, CST 4308), anti-S6 (CST 2217, 1:200), anti-phospho-S6 (Ser235/236, CST 2211, 1:200), anti-GFP (D5.1, CST 2956, 1:200), anti-p-mTOR (D9C2, Ser2448, CST 55365, 1:200), anti-mTOR (CST 2972, 1:200), anti-phospho-4E-BP1 (Ser65, CST 9451, 1:200), and anti-4E-BP1 (53H11, CST 9644, 1:200).</p>
        </sec>
        <sec id="S28">
          <title>Literature meta-analysis</title>
          <p id="P53">Primary studies containing SCLC-specific alteration data were collated according to data availability and alteration profiling method. The patient and alteration counts for each gene were collected from data tables associated with the study where available. For studies without such data tables, the counts were determined by manual annotation of the OncoPrint figures. To determine the number of patients with alteration(s) as well as the total number of patients profiled for each gene, each of the two numbers were summed across all studies, and these two numbers were used to estimate the proportion of SCLC patients possessing an alteration for a given gene. The protein name and amino acid length associated with each gene were obtained through a UniProt DB query, and genes associated with multiple protein notations were each annotated with the overlapping UniProtKB entries (e.g. OR2A1, OR2A42 were both annotated with the UniProtKB entry for Olfactory receptor 2A1/2A42). To examine the expression level for each gene, we collated the data from both human SCLC samples as well as mouse models of SCLC.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> Percentile values for gene expression were determined from each dataset independently. To include a functional output from available <italic toggle="yes">in vitro</italic> experiment data, we also collected gene dependency scores from the CRISPR knockout screens (Achilles) conducted through the DepMap project.<sup><xref rid="R69" ref-type="bibr">69</xref>,<xref rid="R70" ref-type="bibr">70</xref></sup> Cell lines were grouped according to cancer type (SCLC, NSCLC, and all cancers other than SCLC), and the median dependency score was calculated for each gene. AACR GENIE data was obtained from Synapse Platform with written permission.<sup><xref rid="R71" ref-type="bibr">71</xref></sup> For patient samples with multiple alterations (e.g., missense and a frameshift), tally of specific alteration counts in <xref rid="SD2" ref-type="supplementary-material">Table S6</xref> was performed by classifying patient samples by the most disruptive to the least disruptive (with fusion/rearrangement events being considered the most disruptive and synonymous mutations the least disruptive), going from the rightmost column to the leftmost column.</p>
        </sec>
        <sec id="S29">
          <title>Preparation of tuba-seq sgID-BC amplicon libraries</title>
          <p id="P54">Genomic DNA was extracted from tumor-bearing mouse lungs following the addition of three benchmark control cell lines (1 &#215; 10<sup>5</sup> cells per control) as previously described.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> Briefly, the lungs were homogenized and lysed with overnight protease K digestion, and genomic DNA was extracted from the lysate using phenol-chloroform and ethanol precipitation methods. Libraries were prepared by single-step PCR amplification of the sgID-BC region from 32 &#956;g of gDNA per mouse split across eight 100 &#956;L reactions with NEBNext Ultra II Q5 Master Mix (M0544L). Dual index primer pairs with unique i5 and i7 indices were used. PCR products were purified using Sera-Mag Select beads (GE Healthcare Life Sciences 29343052) and assessed for quality with Agilent High Sensitivity DNA kit (Agilent Technologies 5067&#8211;4626) on the Agilent 2100 Bioanalyzer (Agilent Technologies G2939BA). Purified libraries from each mouse were pooled at equal ratios based on lung weight to ensure even sequencing depth per cell, purified once more with Sera-Mag Select beads to remove excess free primers, and sequenced on the Illumina HiSeq 2500 or NextSeq 550 platform (Admera Health Biopharma Services).</p>
        </sec>
        <sec id="S30">
          <title>Tuba-seq analysis</title>
          <p id="P55">We identified the target gene and random barcodes from the sgID-BC region for each tumor cell as previously described.<sup><xref rid="R72" ref-type="bibr">72</xref></sup> The absolute cell number in each tumor was calculated by normalizing the sgID-BC read number by that of the three benchmark control cell lines. We focused on tumors with at least 200 cells and calculated the LNmean (maximum likelihood estimator for mean tumor size assuming log-normal distribution) and tumor number for tumors carrying each target gene deletion. The LNmean and tumor number were normalized to that of Inert tumors to represent the relative growth advantage after inactivating these genes.</p>
        </sec>
        <sec id="S31">
          <title>Laser capture microdissection and tumor clonality analysis</title>
          <p id="P56">7 &#956;M sections from formalin-fixed, paraffin-embedded (FFPE) tissue blocks were cut and mounted on PEN membrane slides (Thermo Fisher LCM0522). Slide was dissected immediately after staining on an Arcturus XT LCM System (Thermo Fisher A26818). The cells in different regions were separated and adhered to CapSure HS LCM Caps (Thermo Fisher LCM0215). Genomic DNA was isolated from these different caps using PicoPure DNA Extraction kit (Thermo Fisher KIT0103). 50 &#956;L lysis buffer with proteinase K were added into each sample and incubated at 65&#176;C overnight. After inactivating proteinase K at 95&#176;C for 10 mins, the genomic DNA was cleaned up with AMPure XP beads at 3:1 ratio (Beckman Coulter A63880) and eluted in the 10 mM Tris-HCl (pH 8.0). The DNA concentration was measured by Qubit<sup>&#174;</sup> dsDNA HS Assay Kit (Thermo Fisher Q32851).</p>
          <p id="P57">sgID-BC amplicon libraries were prepared from genomic DNAs by single-step PCR amplification with NEBNext Ultra II Q5 Master Mix (M0544L) using dual indexing primer pairs. PCR products were purified first using MinElute PCR Purification Kit (Qiagen 28006), then with Agencourt AMPure XP beads (Beckman Coulter A63881) and assessed for quality with Agilent High Sensitivity DNA kit on the Agilent 2100 Bioanalyzer prior to sequencing on the Illumina MiSeq Nano platform (Admera Health Biopharma Services).</p>
        </sec>
        <sec id="S32">
          <title>RNA-seq analysis</title>
          <p id="P58">Tumor-derived cell lines were snap frozen and submitted for RNA analysis. Total RNA isolation, polyA selection, quality control, library preparation, and sequencing were performed by Azenta using Illumina HiSeq platform (2 &#215; 150 bp, ~350M paired-end reads). Transcript quantification for the RNA-seq data was conducted with Salmon (v0.12.0)<sup><xref rid="R64" ref-type="bibr">64</xref></sup> with mouse genome version GRCm38. DESeq2 (v1.34.0) was used to calculate differential expression across the mouse tumor-derived cell lines.<sup><xref rid="R65" ref-type="bibr">65</xref></sup></p>
        </sec>
      </sec>
      <sec id="S33">
        <title>QUANTIFICATION AND STATISTICAL ANALYSIS</title>
        <p id="P59">ClueGo plugin (v2.5.6) running on Cytoscape (v3.8.0)<sup><xref rid="R66" ref-type="bibr">66</xref>,<xref rid="R67" ref-type="bibr">67</xref></sup> was used to determine pathways enriched for 3285 genes that had been profiled for alterations on &#8805;250 patients, having an alteration proportion of &#8805;0.03, and coding for proteins &#8804;2000 amino acid residues long. Bonferroni step-down correction was applied on two-sided hypergeometric test to determine statistical significance. All other statistical details of experiments can be found in the figure legends. Unless otherwise indicated, all other statistical analyses were performed using GraphPad Prism (v9.1.0) for Windows (GraphPad Software, San Diego, California USA). Data are represented as mean &#177; standard error of the mean unless otherwise stated.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material" id="SM1">
      <title>Supplementary Material</title>
      <supplementary-material id="SD1" position="float" content-type="local-data">
        <label>1</label>
        <media ns1:href="NIHMS1872761-supplement-1.pdf" id="d64e1842" position="anchor" />
      </supplementary-material>
      <supplementary-material id="SD2" position="float" content-type="local-data">
        <label>2</label>
        <media ns1:href="NIHMS1872761-supplement-2.zip" id="d64e1845" position="anchor" />
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S34">
      <title>ACKNOWLEDGMENTS</title>
      <p id="P60">We thank Alyssa Ray for administrative support; Dr. Trudy Oliver for sharing the <italic toggle="yes">RPM</italic> mouse model; Pauline Chu and the Animal Histology Service Center at Stanford University for help with histology; the Stanford Shared FACS Facility for flow cytometry services (NIH S10 Shared Instrument Grant S10RR027431-01); the Stanford Veterinary Service Center for expert animal care; the Stanford Genomics Service Center as well as the Protein and Nucleic Acid Facility for help with Bioanalyzer runs; Hyoeun Jung for helping generate illustrations and organize the figures; and all the members of the laboratory of J.S. and M.M.W. for their help and support throughout this study. This work was supported by the NIH (grants CA231997 and CA217450 to J.S.; grants R01-CA207133, R01-CA231253, and R01-CA234349 to M.M.W. and D.A.P.; and grant F31CA257169-01 to J.H.K.), the Stanford Cancer Institute (NIH grant P30-CA124435), and the Agency for Science, Technology and Research (A*STAR) Singapore (Y.T.S.). M.C.L. was supported by the Tom and Susan Ford Stanford Graduate Fellowship in Science and Engineering and Tobacco-Related Disease Research Program (TRDRP) Predoctoral Fellowship (T32DT4747). H.C. was supported by a TRDRP Postdoctoral Fellowship (28FT-0019). C.W.M. was supported by the NSF Graduate Research Fellowship Program and an Anne T. and Robert M. Bass Stanford Graduate Fellowship. C.L. was the Connie and Bob Lurie Fellow of the Damon Runyon Cancer Research Foundation (DRG-2331). D.A.P. is a Chan Zuckerberg Biohub investigator. J.S. is the Elaine and John Chambers Professor in Pediatric Cancer. The authors would like to acknowledge the NCI Small Cell Lung Cancer Conortium (grant U24 CA213274) and the AACR Project GENIE registry for sharing SCLC data; interpretations are the responsibility of study authors.</p>
    </ack>
    <fn-group>
      <fn id="FN2">
        <p id="P62">SUPPLEMENTAL INFORMATION</p>
        <p id="P63">Supplemental information can be found online at <ext-link ns1:href="10.1016/j.celrep.2023.111990" ext-link-type="doi">https://doi.org/10.1016/j.celrep.2023.111990</ext-link>.</p>
      </fn>
      <fn fn-type="COI-statement" id="FN3">
        <p id="P64">DECLARATION OF INTERESTS</p>
        <p id="P65">J.S. has equity in and is an advisor for DISCO Pharmaceuticals. M.M.W. and D.A.P. are founders of and hold equity in D2G Oncology.</p>
      </fn>
    </fn-group>
    <app-group>
      <app id="APP1">
        <title>INCLUSION AND DIVERSITY</title>
        <p id="P61">We support inclusive, diverse, and equitable conduct of research.</p>
      </app>
    </app-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><name><surname>Beasley</surname><given-names>MB</given-names></name>, <name><surname>Brambilla</surname><given-names>E</given-names></name>, and <name><surname>Travis</surname><given-names>WD</given-names></name> (<year>2005</year>). <article-title>The 2004 World Health Organization classification of lung tumors</article-title>. <source>Semin. Roentgenol</source>
<volume>40</volume>, <fpage>90</fpage>&#8211;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1053/j.ro.2005.01.001</pub-id>.<pub-id pub-id-type="pmid">15898407</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><name><surname>Travis</surname><given-names>WD</given-names></name>, <name><surname>Brambilla</surname><given-names>E</given-names></name>, <name><surname>Nicholson</surname><given-names>AG</given-names></name>, <name><surname>Yatabe</surname><given-names>Y</given-names></name>, <name><surname>Austin</surname><given-names>JHM</given-names></name>, <name><surname>Beasley</surname><given-names>MB</given-names></name>, <name><surname>Chirieac</surname><given-names>LR</given-names></name>, <name><surname>Dacic</surname><given-names>S</given-names></name>, <name><surname>Duhig</surname><given-names>E</given-names></name>, <name><surname>Flieder</surname><given-names>DB</given-names></name>, <etal /> (<year>2015</year>). <article-title>The 2015 world Health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification</article-title>. <source>J. Thorac. Oncol</source>
<volume>10</volume>, <fpage>1243</fpage>&#8211;<lpage>1260</lpage>. <pub-id pub-id-type="doi">10.1097/JTO.0000000000000630</pub-id>.<pub-id pub-id-type="pmid">26291008</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><name><surname>Barnholtz-Sloan</surname><given-names>JS</given-names></name>, <name><surname>Sloan</surname><given-names>AE</given-names></name>, <name><surname>Davis</surname><given-names>FG</given-names></name>, <name><surname>Vigneau</surname><given-names>FD</given-names></name>, <name><surname>Lai</surname><given-names>P</given-names></name>, and <name><surname>Sawaya</surname><given-names>RE</given-names></name> (<year>2004</year>). <article-title>Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system</article-title>. <source>J. Clin. Oncol</source>
<volume>22</volume>, <fpage>2865</fpage>&#8211;<lpage>2872</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2004.12.149</pub-id>.<pub-id pub-id-type="pmid">15254054</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><name><surname>Reck</surname><given-names>M</given-names></name>, <name><surname>Luft</surname><given-names>A</given-names></name>, <name><surname>Szczesna</surname><given-names>A</given-names></name>, <name><surname>Havel</surname><given-names>L</given-names></name>, <name><surname>Kim</surname><given-names>S-W</given-names></name>, <name><surname>Akerley</surname><given-names>W</given-names></name>, <name><surname>Pietanza</surname><given-names>MC</given-names></name>, <name><surname>Wu</surname><given-names>YL</given-names></name>, <name><surname>Zielinski</surname><given-names>C</given-names></name>, <name><surname>Thomas</surname><given-names>M</given-names></name>, <etal /> (<year>2016</year>). <article-title>Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer</article-title>. <source>J. Clin. Oncol</source>
<volume>34</volume>, <fpage>3740</fpage>&#8211;<lpage>3748</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2016.67.6601</pub-id>.<pub-id pub-id-type="pmid">27458307</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><name><surname>George</surname><given-names>J</given-names></name>, <name><surname>Lim</surname><given-names>JS</given-names></name>, <name><surname>Jang</surname><given-names>SJ</given-names></name>, <name><surname>Cun</surname><given-names>Y</given-names></name>, <name><surname>Ozreti&#263;</surname><given-names>L</given-names></name>, <name><surname>Kong</surname><given-names>G</given-names></name>, <name><surname>Leenders</surname><given-names>F</given-names></name>, <name><surname>Lu</surname><given-names>X</given-names></name>, <name><surname>Fern&#225;ndez-Cuesta</surname><given-names>L</given-names></name>, <name><surname>Bosco</surname><given-names>G</given-names></name>, <etal /> (<year>2015</year>). <article-title>Comprehensive genomic profiles of small cell lung cancer</article-title>. <source>Nature</source>
<volume>524</volume>, <fpage>47</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1038/nature14664</pub-id>.<pub-id pub-id-type="pmid">26168399</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><name><surname>Howlader</surname><given-names>N</given-names></name>, <name><surname>Forjaz</surname><given-names>G</given-names></name>, <name><surname>Mooradian</surname><given-names>MJ</given-names></name>, <name><surname>Meza</surname><given-names>R</given-names></name>, <name><surname>Kong</surname><given-names>CY</given-names></name>, <name><surname>Cronin</surname><given-names>KA</given-names></name>, <name><surname>Mariotto</surname><given-names>AB</given-names></name>, <name><surname>Lowy</surname><given-names>DR</given-names></name>, and <name><surname>Feuer</surname><given-names>EJ</given-names></name> (<year>2020</year>). <article-title>The effect of advances in lung-cancer treatment on population mortality</article-title>. <source>N. Engl. J. Med</source>
<volume>383</volume>, <fpage>640</fpage>&#8211;<lpage>649</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1916623</pub-id>.<pub-id pub-id-type="pmid">32786189</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><name><surname>Mollaoglu</surname><given-names>G</given-names></name>, <name><surname>Guthrie</surname><given-names>MR</given-names></name>, <name><surname>B&#246;hm</surname><given-names>S</given-names></name>, <name><surname>Br&#228;gelmann</surname><given-names>J</given-names></name>, <name><surname>Can</surname><given-names>I</given-names></name>, <name><surname>Ballieu</surname><given-names>PM</given-names></name>, <name><surname>Marx</surname><given-names>A</given-names></name>, <name><surname>George</surname><given-names>J</given-names></name>, <name><surname>Heinen</surname><given-names>C</given-names></name>, <name><surname>Chalishazar</surname><given-names>MD</given-names></name>, <etal /> (<year>2017</year>). <article-title>MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition</article-title>. <source>Cancer Cell</source>
<volume>31</volume>, <fpage>270</fpage>&#8211;<lpage>285</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2016.12.005</pub-id>.<pub-id pub-id-type="pmid">28089889</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><name><surname>Augert</surname><given-names>A</given-names></name>, <name><surname>Zhang</surname><given-names>Q</given-names></name>, <name><surname>Bates</surname><given-names>B</given-names></name>, <name><surname>Cui</surname><given-names>M</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Wildey</surname><given-names>G</given-names></name>, <name><surname>Dowlati</surname><given-names>A</given-names></name>, and <name><surname>MacPherson</surname><given-names>D</given-names></name> (<year>2017</year>). <article-title>Small cell lung cancer exhibits frequent inactivating mutations in the histone methyltransferase KMT2D/MLL2: CALGB 151111 (alliance)</article-title>. <source>J. Thorac. Oncol</source>
<volume>12</volume>, <fpage>704</fpage>&#8211;<lpage>713</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtho.2016.12.011</pub-id>.<pub-id pub-id-type="pmid">28007623</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><name><surname>Peifer</surname><given-names>M</given-names></name>, <name><surname>Fern&#225;ndez-Cuesta</surname><given-names>L</given-names></name>, <name><surname>Sos</surname><given-names>ML</given-names></name>, <name><surname>George</surname><given-names>J</given-names></name>, <name><surname>Seidel</surname><given-names>D</given-names></name>, <name><surname>Kasper</surname><given-names>LH</given-names></name>, <name><surname>Plenker</surname><given-names>D</given-names></name>, <name><surname>Leenders</surname><given-names>F</given-names></name>, <name><surname>Sun</surname><given-names>R</given-names></name>, <name><surname>Zander</surname><given-names>T</given-names></name>, <etal /> (<year>2012</year>). <article-title>Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer</article-title>. <source>Nat. Genet</source>
<volume>44</volume>, <fpage>1104</fpage>&#8211;<lpage>1110</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2396</pub-id>.<pub-id pub-id-type="pmid">22941188</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><name><surname>Calbo</surname><given-names>J</given-names></name>, <name><surname>van Montfort</surname><given-names>E</given-names></name>, <name><surname>Proost</surname><given-names>N</given-names></name>, <name><surname>van Drunen</surname><given-names>E</given-names></name>, <name><surname>Beverloo</surname><given-names>HB</given-names></name>, <name><surname>Meuwissen</surname><given-names>R</given-names></name>, and <name><surname>Berns</surname><given-names>A</given-names></name> (<year>2011</year>). <article-title>A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer</article-title>. <source>Cancer Cell</source>
<volume>19</volume>, <fpage>244</fpage>&#8211;<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2010.12.021</pub-id>.<pub-id pub-id-type="pmid">21316603</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><name><surname>Schaffer</surname><given-names>BE</given-names></name>, <name><surname>Park</surname><given-names>K-S</given-names></name>, <name><surname>Yiu</surname><given-names>G</given-names></name>, <name><surname>Conklin</surname><given-names>JF</given-names></name>, <name><surname>Lin</surname><given-names>C</given-names></name>, <name><surname>Burkhart</surname><given-names>DL</given-names></name>, <name><surname>Karnezis</surname><given-names>AN</given-names></name>, <name><surname>Sweet-Cordero</surname><given-names>EA</given-names></name>, and <name><surname>Sage</surname><given-names>J</given-names></name> (<year>2010</year>). <article-title>Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma</article-title>. <source>Cancer Res</source>. <volume>70</volume>, <fpage>3877</fpage>&#8211;<lpage>3883</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-4228</pub-id>.<pub-id pub-id-type="pmid">20406986</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><name><surname>Meuwissen</surname><given-names>R</given-names></name>, <name><surname>Linn</surname><given-names>SC</given-names></name>, <name><surname>Linnoila</surname><given-names>RI</given-names></name>, <name><surname>Zevenhoven</surname><given-names>J</given-names></name>, <name><surname>Mooi</surname><given-names>WJ</given-names></name>, and <name><surname>Berns</surname><given-names>A</given-names></name> (<year>2003</year>). <article-title>Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model</article-title>. <source>Cancer Cell</source>
<volume>4</volume>, <fpage>181</fpage>&#8211;<lpage>189</lpage>. <pub-id pub-id-type="doi">10.1016/S1535-6108(03)00220-4</pub-id>.<pub-id pub-id-type="pmid">14522252</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><name><surname>Cui</surname><given-names>M</given-names></name>, <name><surname>Augert</surname><given-names>A</given-names></name>, <name><surname>Rongione</surname><given-names>M</given-names></name>, <name><surname>Conkrite</surname><given-names>K</given-names></name>, <name><surname>Parazzoli</surname><given-names>S</given-names></name>, <name><surname>Nikitin</surname><given-names>AY</given-names></name>, <name><surname>Ingolia</surname><given-names>N</given-names></name>, and <name><surname>MacPherson</surname><given-names>D</given-names></name> (<year>2014</year>). <article-title>PTEN is a potent suppressor of small cell lung cancer</article-title>. <source>Mol. Cancer Res</source>
<volume>12</volume>, <fpage>654</fpage>&#8211;<lpage>659</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-13-0554</pub-id>.<pub-id pub-id-type="pmid">24482365</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>D-W</given-names></name>, <name><surname>Wu</surname><given-names>N</given-names></name>, <name><surname>Kim</surname><given-names>Y-C</given-names></name>, <name><surname>Cheng</surname><given-names>PF</given-names></name>, <name><surname>Basom</surname><given-names>R</given-names></name>, <name><surname>Kim</surname><given-names>D</given-names></name>, <name><surname>Dunn</surname><given-names>CT</given-names></name>, <name><surname>Lee</surname><given-names>AY</given-names></name>, <name><surname>Kim</surname><given-names>K</given-names></name>, <name><surname>Lee</surname><given-names>CS</given-names></name>, <etal /> (<year>2016</year>). <article-title>Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer</article-title>. <source>Genes Dev</source>. <volume>30</volume>, <fpage>1289</fpage>&#8211;<lpage>1299</lpage>. <pub-id pub-id-type="doi">10.1101/gad.279307.116</pub-id>.<pub-id pub-id-type="pmid">27298335</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><name><surname>Denny</surname><given-names>SK</given-names></name>, <name><surname>Yang</surname><given-names>D</given-names></name>, <name><surname>Chuang</surname><given-names>C-H</given-names></name>, <name><surname>Brady</surname><given-names>JJ</given-names></name>, <name><surname>Lim</surname><given-names>JS</given-names></name>, <name><surname>Gr&#252;ner</surname><given-names>BM</given-names></name>, <name><surname>Chiou</surname><given-names>S-H</given-names></name>, <name><surname>Schep</surname><given-names>AN</given-names></name>, <name><surname>Baral</surname><given-names>J</given-names></name>, <name><surname>Hamard</surname><given-names>C</given-names></name>, <etal /> (<year>2016</year>). <article-title>Nfib promotes metastasis through a widespread increase in chromatin accessibility</article-title>. <source>Cell</source>
<volume>166</volume>, <fpage>328</fpage>&#8211;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.05.052</pub-id>.<pub-id pub-id-type="pmid">27374332</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><name><surname>Jia</surname><given-names>D</given-names></name>, <name><surname>Augert</surname><given-names>A</given-names></name>, <name><surname>Kim</surname><given-names>D-W</given-names></name>, <name><surname>Eastwood</surname><given-names>E</given-names></name>, <name><surname>Wu</surname><given-names>N</given-names></name>, <name><surname>Ibrahim</surname><given-names>AH</given-names></name>, <name><surname>Kim</surname><given-names>K-B</given-names></name>, <name><surname>Dunn</surname><given-names>CT</given-names></name>, <name><surname>Pillai</surname><given-names>SPS</given-names></name>, <name><surname>Gazdar</surname><given-names>AF</given-names></name>, <etal /> (<year>2018</year>). <article-title>Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition</article-title>. <source>Cancer Discov</source>. <volume>8</volume>, <fpage>1422</fpage>&#8211;<lpage>1437</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-0385</pub-id>.<pub-id pub-id-type="pmid">30181244</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><name><surname>Coles</surname><given-names>GL</given-names></name>, <name><surname>Cristea</surname><given-names>S</given-names></name>, <name><surname>Webber</surname><given-names>JT</given-names></name>, <name><surname>Levin</surname><given-names>RS</given-names></name>, <name><surname>Moss</surname><given-names>SM</given-names></name>, <name><surname>He</surname><given-names>A</given-names></name>, <name><surname>Sangodkar</surname><given-names>J</given-names></name>, <name><surname>Hwang</surname><given-names>YC</given-names></name>, <name><surname>Arand</surname><given-names>J</given-names></name>, <name><surname>Drainas</surname><given-names>AP</given-names></name>, <etal /> (<year>2020</year>). <article-title>Unbiased proteomic profiling uncovers a targetable GNAS/PKA/PP2A Axis in small cell lung cancer stem cells</article-title>. <source>Cancer Cell</source>
<volume>38</volume>, <fpage>129</fpage>&#8211;<lpage>143.e7</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2020.05.003</pub-id>.<pub-id pub-id-type="pmid">32531271</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><name><surname>Ciampricotti</surname><given-names>M</given-names></name>, <name><surname>Karakousi</surname><given-names>T</given-names></name>, <name><surname>Richards</surname><given-names>AL</given-names></name>, <name><surname>Quintanal-Villalonga</surname><given-names>&#192;</given-names></name>, <name><surname>Karatza</surname><given-names>A</given-names></name>, <name><surname>Caeser</surname><given-names>R</given-names></name>, <name><surname>Costa</surname><given-names>EA</given-names></name>, <name><surname>Allaj</surname><given-names>V</given-names></name>, <name><surname>Manoj</surname><given-names>P</given-names></name>, <name><surname>Spainhower</surname><given-names>KB</given-names></name>, <etal /> (<year>2021</year>). <article-title>Rlf&#8211;mycl gene fusion drives tumorigenesis and metastasis in a mouse model of small cell lung cancer</article-title>. <source>Cancer Discov</source>. <volume>11</volume>, <fpage>3214</fpage>&#8211;<lpage>3229</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-0441</pub-id>.<pub-id pub-id-type="pmid">34344693</pub-id></mixed-citation>
      </ref>
      <ref id="R19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><name><surname>Ferone</surname><given-names>G</given-names></name>, <name><surname>Lee</surname><given-names>MC</given-names></name>, <name><surname>Sage</surname><given-names>J</given-names></name>, and <name><surname>Berns</surname><given-names>A</given-names></name> (<year>2020</year>). <article-title>Cells of origin of lung cancers: lessons from mouse studies</article-title>. <source>Genes Dev</source>. <volume>34</volume>, <fpage>1017</fpage>&#8211;<lpage>1032</lpage>. <pub-id pub-id-type="doi">10.1101/gad.338228.120</pub-id>.<pub-id pub-id-type="pmid">32747478</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><name><surname>Rogers</surname><given-names>ZN</given-names></name>, <name><surname>McFarland</surname><given-names>CD</given-names></name>, <name><surname>Winters</surname><given-names>IP</given-names></name>, <name><surname>Naranjo</surname><given-names>S</given-names></name>, <name><surname>Chuang</surname><given-names>C-H</given-names></name>, <name><surname>Petrov</surname><given-names>D</given-names></name>, and <name><surname>Winslow</surname><given-names>MM</given-names></name> (<year>2017</year>). <article-title>A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression <italic toggle="yes">in vivo</italic></article-title>. <source>Nat. Methods</source>
<volume>14</volume>, <fpage>737</fpage>&#8211;<lpage>742</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.4297</pub-id>.<pub-id pub-id-type="pmid">28530655</pub-id></mixed-citation>
      </ref>
      <ref id="R21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><name><surname>Murray</surname><given-names>CW</given-names></name>, <name><surname>Brady</surname><given-names>JJ</given-names></name>, <name><surname>Tsai</surname><given-names>MK</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Winters</surname><given-names>IP</given-names></name>, <name><surname>Tang</surname><given-names>R</given-names></name>, <name><surname>Andrejka</surname><given-names>L</given-names></name>, <name><surname>Ma</surname><given-names>RK</given-names></name>, <name><surname>Kunder</surname><given-names>CA</given-names></name>, <name><surname>Chu</surname><given-names>P</given-names></name>, and <name><surname>Winslow</surname><given-names>MM</given-names></name> (<year>2019</year>). <article-title>An Lkb1-Sik axis suppresses lung tumor growth and controls differentiation</article-title>. <source>Cancer Discov</source>. <volume>9</volume>, <fpage>1590</fpage>&#8211;<lpage>1605</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290</pub-id>.<pub-id pub-id-type="pmid">31350327</pub-id></mixed-citation>
      </ref>
      <ref id="R22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><name><surname>Rudin</surname><given-names>CM</given-names></name>, <name><surname>Poirier</surname><given-names>JT</given-names></name>, <name><surname>Byers</surname><given-names>LA</given-names></name>, <name><surname>Dive</surname><given-names>C</given-names></name>, <name><surname>Dowlati</surname><given-names>A</given-names></name>, <name><surname>George</surname><given-names>J</given-names></name>, <name><surname>Heymach</surname><given-names>JV</given-names></name>, <name><surname>Johnson</surname><given-names>JE</given-names></name>, <name><surname>Lehman</surname><given-names>JM</given-names></name>, <name><surname>MacPherson</surname><given-names>D</given-names></name>, <etal /> (<year>2019</year>). <article-title>Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data</article-title>. <source>Nat. Rev. Cancer</source>
<volume>19</volume>, <fpage>289</fpage>&#8211;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1038/s41568-019-0133-9</pub-id>.<pub-id pub-id-type="pmid">30926931</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><name><surname>Gazdar</surname><given-names>AF</given-names></name>, <name><surname>Savage</surname><given-names>TK</given-names></name>, <name><surname>Johnson</surname><given-names>JE</given-names></name>, <name><surname>Berns</surname><given-names>A</given-names></name>, <name><surname>Sage</surname><given-names>J</given-names></name>, <name><surname>Linnoila</surname><given-names>RI</given-names></name>, <name><surname>MacPherson</surname><given-names>D</given-names></name>, <name><surname>McFadden</surname><given-names>DG</given-names></name>, <name><surname>Farago</surname><given-names>A</given-names></name>, <name><surname>Jacks</surname><given-names>T</given-names></name>, <etal /> (<year>2015</year>). <article-title>The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung</article-title>. <source>J. Thorac. Oncol</source>
<volume>10</volume>, <fpage>553</fpage>&#8211;<lpage>564</lpage>. <pub-id pub-id-type="doi">10.1097/JTO.0000000000000459</pub-id>.<pub-id pub-id-type="pmid">25675280</pub-id></mixed-citation>
      </ref>
      <ref id="R24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><name><surname>Van Winkle</surname><given-names>LS</given-names></name>, <name><surname>Buckpitt</surname><given-names>AR</given-names></name>, <name><surname>Nishio</surname><given-names>SJ</given-names></name>, <name><surname>Isaac</surname><given-names>JM</given-names></name>, and <name><surname>Plopper</surname><given-names>CG</given-names></name> (<year>1995</year>). <article-title>Cellular response in naphthalene-induced Clara cell injury and bronchiolar epithelial repair in mice</article-title>. <source>Am. J. Physiol</source>
<volume>269</volume>, <fpage>L800</fpage>&#8211;<lpage>L818</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.1995.269.6.L800</pub-id>.<pub-id pub-id-type="pmid">8572242</pub-id></mixed-citation>
      </ref>
      <ref id="R25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><name><surname>Xia</surname><given-names>Y</given-names></name>, <name><surname>Zhan</surname><given-names>C</given-names></name>, <name><surname>Feng</surname><given-names>M</given-names></name>, <name><surname>Leblanc</surname><given-names>M</given-names></name>, <name><surname>Ke</surname><given-names>E</given-names></name>, <name><surname>Yeddula</surname><given-names>N</given-names></name>, and <name><surname>Verma</surname><given-names>IM</given-names></name> (<year>2018</year>). <article-title>Targeting CREB pathway suppresses small cell lung cancer</article-title>. <source>Mol. Cancer Res</source>
<volume>16</volume>, <fpage>825</fpage>&#8211;<lpage>832</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-17-0576</pub-id>.<pub-id pub-id-type="pmid">29523765</pub-id></mixed-citation>
      </ref>
      <ref id="R26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>D</given-names></name>, <name><surname>Denny</surname><given-names>SK</given-names></name>, <name><surname>Greenside</surname><given-names>PG</given-names></name>, <name><surname>Chaikovsky</surname><given-names>AC</given-names></name>, <name><surname>Brady</surname><given-names>JJ</given-names></name>, <name><surname>Ouadah</surname><given-names>Y</given-names></name>, <name><surname>Granja</surname><given-names>JM</given-names></name>, <name><surname>Jahchan</surname><given-names>NS</given-names></name>, <name><surname>Lim</surname><given-names>JS</given-names></name>, <name><surname>Kwok</surname><given-names>S</given-names></name>, <etal /> (<year>2018</year>). <article-title>Intertumoral heterogeneity in SCLC is influenced by the cell type of origin</article-title>. <source>Cancer Discov</source>. <volume>8</volume>, <fpage>1316</fpage>&#8211;<lpage>1331</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0987</pub-id>.<pub-id pub-id-type="pmid">30228179</pub-id></mixed-citation>
      </ref>
      <ref id="R27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><name><surname>Wagner</surname><given-names>AH</given-names></name>, <name><surname>Devarakonda</surname><given-names>S</given-names></name>, <name><surname>Skidmore</surname><given-names>ZL</given-names></name>, <name><surname>Krysiak</surname><given-names>K</given-names></name>, <name><surname>Ramu</surname><given-names>A</given-names></name>, <name><surname>Trani</surname><given-names>L</given-names></name>, <name><surname>Kunisaki</surname><given-names>J</given-names></name>, <name><surname>Masood</surname><given-names>A</given-names></name>, <name><surname>Waqar</surname><given-names>SN</given-names></name>, <name><surname>Spies</surname><given-names>NC</given-names></name>, <etal /> (<year>2018</year>). <article-title>Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer</article-title>. <source>Nat. Commun</source>
<volume>9</volume>, <fpage>3787</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-06162-9</pub-id>.<pub-id pub-id-type="pmid">30224629</pub-id></mixed-citation>
      </ref>
      <ref id="R28">
        <label>28.</label>
        <mixed-citation publication-type="journal"><name><surname>Hollander</surname><given-names>MC</given-names></name>, <name><surname>Philburn</surname><given-names>RT</given-names></name>, <name><surname>Patterson</surname><given-names>AD</given-names></name>, <name><surname>Velasco-Miguel</surname><given-names>S</given-names></name>, <name><surname>Friedberg</surname><given-names>EC</given-names></name>, <name><surname>Linnoila</surname><given-names>RI</given-names></name>, and <name><surname>Fornace</surname><given-names>AJ</given-names></name> (<year>2005</year>). <article-title>Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>
<volume>102</volume>, <fpage>13200</fpage>&#8211;<lpage>13205</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0503133102</pub-id>.<pub-id pub-id-type="pmid">16141330</pub-id></mixed-citation>
      </ref>
      <ref id="R29">
        <label>29.</label>
        <mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>S</given-names></name>, <name><surname>Lee</surname><given-names>H</given-names></name>, <name><surname>Lee</surname><given-names>B</given-names></name>, <name><surname>Lee</surname><given-names>S-H</given-names></name>, <name><surname>Sun</surname><given-names>J-M</given-names></name>, <name><surname>Park</surname><given-names>W-Y</given-names></name>, <name><surname>Ahn</surname><given-names>JS</given-names></name>, <name><surname>Ahn</surname><given-names>M-J</given-names></name>, and <name><surname>Park</surname><given-names>K</given-names></name> (<year>2019</year>). <article-title>DNA damage response and repair pathway alteration and its association with tumor mutation burden and platinum-based chemotherapy in SCLC</article-title>. <source>J. Thorac. Oncol</source>
<volume>14</volume>, <fpage>1640</fpage>&#8211;<lpage>1650</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtho.2019.05.014</pub-id>.<pub-id pub-id-type="pmid">31125737</pub-id></mixed-citation>
      </ref>
      <ref id="R30">
        <label>30.</label>
        <mixed-citation publication-type="journal"><name><surname>Jaskulski</surname><given-names>D</given-names></name>, <name><surname>deRiel</surname><given-names>JK</given-names></name>, <name><surname>Mercer</surname><given-names>WE</given-names></name>, <name><surname>Calabretta</surname><given-names>B</given-names></name>, and <name><surname>Baserga</surname><given-names>R</given-names></name> (<year>1988</year>). <article-title>Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin</article-title>. <source>Science</source>
<volume>240</volume>, <fpage>1544</fpage>&#8211;<lpage>1546</lpage>. <pub-id pub-id-type="doi">10.1126/science.2897717</pub-id>.<pub-id pub-id-type="pmid">2897717</pub-id></mixed-citation>
      </ref>
      <ref id="R31">
        <label>31.</label>
        <mixed-citation publication-type="journal"><name><surname>Nellist</surname><given-names>M</given-names></name>, <name><surname>van Slegtenhorst</surname><given-names>MA</given-names></name>, <name><surname>Goedbloed</surname><given-names>M</given-names></name>, <name><surname>van den Ouweland</surname><given-names>AM</given-names></name>, <name><surname>Halley</surname><given-names>DJ</given-names></name>, and <name><surname>van der Sluijs</surname><given-names>P</given-names></name> (<year>1999</year>). <article-title>Characterization of the cytosolic tuberin-hamartin complex: tuberin IS a cytosolic chaperone for hamartin</article-title>. <source>J. Biol. Chem</source>
<volume>274</volume>, <fpage>35647</fpage>&#8211;<lpage>35652</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.50.35647</pub-id>.<pub-id pub-id-type="pmid">10585443</pub-id></mixed-citation>
      </ref>
      <ref id="R32">
        <label>32.</label>
        <mixed-citation publication-type="journal"><name><surname>Rovira-Clav&#233;</surname><given-names>X</given-names></name>, <name><surname>Drainas</surname><given-names>AP</given-names></name>, <name><surname>Jiang</surname><given-names>S</given-names></name>, <name><surname>Bai</surname><given-names>Y</given-names></name>, <name><surname>Baron</surname><given-names>M</given-names></name>, <name><surname>Zhu</surname><given-names>B</given-names></name>, <name><surname>Dallas</surname><given-names>AE</given-names></name>, <name><surname>Lee</surname><given-names>MC</given-names></name>, <name><surname>Chu</surname><given-names>TP</given-names></name>, <name><surname>Holzem</surname><given-names>A</given-names></name>, <etal /> (<year>2022</year>). <article-title>Spatial epitope barcoding reveals clonal tumor patch behaviors</article-title>. <source>Cancer Cell</source>
<volume>40</volume>, <fpage>1423</fpage>&#8211;<lpage>1439.e11</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2022.09.014</pub-id>.<pub-id pub-id-type="pmid">36240778</pub-id></mixed-citation>
      </ref>
      <ref id="R33">
        <label>33.</label>
        <mixed-citation publication-type="journal"><name><surname>Wagenblast</surname><given-names>E</given-names></name>, <name><surname>Soto</surname><given-names>M</given-names></name>, <name><surname>Guti&#233;rrez-&#193;ngel</surname><given-names>S</given-names></name>, <name><surname>Hartl</surname><given-names>CA</given-names></name>, <name><surname>Gable</surname><given-names>AL</given-names></name>, <name><surname>Maceli</surname><given-names>AR</given-names></name>, <name><surname>Erard</surname><given-names>N</given-names></name>, <name><surname>Williams</surname><given-names>AM</given-names></name>, <name><surname>Kim</surname><given-names>SY</given-names></name>, <name><surname>Dickopf</surname><given-names>S</given-names></name>, <etal /> (<year>2015</year>). <article-title>A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis</article-title>. <source>Nature</source>
<volume>520</volume>, <fpage>358</fpage>&#8211;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1038/nature14403</pub-id>.<pub-id pub-id-type="pmid">25855289</pub-id></mixed-citation>
      </ref>
      <ref id="R34">
        <label>34.</label>
        <mixed-citation publication-type="journal"><name><surname>Nguyen</surname><given-names>LV</given-names></name>, <name><surname>Pellacani</surname><given-names>D</given-names></name>, <name><surname>Lefort</surname><given-names>S</given-names></name>, <name><surname>Kannan</surname><given-names>N</given-names></name>, <name><surname>Osako</surname><given-names>T</given-names></name>, <name><surname>Makarem</surname><given-names>M</given-names></name>, <name><surname>Cox</surname><given-names>CL</given-names></name>, <name><surname>Kennedy</surname><given-names>W</given-names></name>, <name><surname>Beer</surname><given-names>P</given-names></name>, <name><surname>Carles</surname><given-names>A</given-names></name>, <etal /> (<year>2015</year>). <article-title>Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells</article-title>. <source>Nature</source>
<volume>528</volume>, <fpage>267</fpage>&#8211;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1038/nature15742</pub-id>.<pub-id pub-id-type="pmid">26633636</pub-id></mixed-citation>
      </ref>
      <ref id="R35">
        <label>35.</label>
        <mixed-citation publication-type="journal"><name><surname>Dixit</surname><given-names>A</given-names></name>, <name><surname>Parnas</surname><given-names>O</given-names></name>, <name><surname>Li</surname><given-names>B</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Fulco</surname><given-names>CP</given-names></name>, <name><surname>Jerby-Arnon</surname><given-names>L</given-names></name>, <name><surname>Marjanovic</surname><given-names>ND</given-names></name>, <name><surname>Dionne</surname><given-names>D</given-names></name>, <name><surname>Burks</surname><given-names>T</given-names></name>, <name><surname>Raychowdhury</surname><given-names>R</given-names></name>, <etal /> (<year>2016</year>). <article-title>Perturb-seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens</article-title>. <source>Cell</source>
<volume>167</volume>, <fpage>1853</fpage>&#8211;<lpage>1866.e17</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.11.038</pub-id>.<pub-id pub-id-type="pmid">27984732</pub-id></mixed-citation>
      </ref>
      <ref id="R36">
        <label>36.</label>
        <mixed-citation publication-type="journal"><name><surname>Zehir</surname><given-names>A</given-names></name>, <name><surname>Benayed</surname><given-names>R</given-names></name>, <name><surname>Shah</surname><given-names>RH</given-names></name>, <name><surname>Syed</surname><given-names>A</given-names></name>, <name><surname>Middha</surname><given-names>S</given-names></name>, <name><surname>Kim</surname><given-names>HR</given-names></name>, <name><surname>Srinivasan</surname><given-names>P</given-names></name>, <name><surname>Gao</surname><given-names>J</given-names></name>, <name><surname>Chakravarty</surname><given-names>D</given-names></name>, <name><surname>Devlin</surname><given-names>SM</given-names></name>, <etal /> (<year>2017</year>). <article-title>Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</article-title>. <source>Nat. Med</source>
<volume>23</volume>, <fpage>703</fpage>&#8211;<lpage>713</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4333</pub-id>.<pub-id pub-id-type="pmid">28481359</pub-id></mixed-citation>
      </ref>
      <ref id="R37">
        <label>37.</label>
        <mixed-citation publication-type="journal"><name><surname>Bolton</surname><given-names>KL</given-names></name>, <name><surname>Ptashkin</surname><given-names>RN</given-names></name>, <name><surname>Gao</surname><given-names>T</given-names></name>, <name><surname>Braunstein</surname><given-names>L</given-names></name>, <name><surname>Devlin</surname><given-names>SM</given-names></name>, <name><surname>Kelly</surname><given-names>D</given-names></name>, <name><surname>Patel</surname><given-names>M</given-names></name>, <name><surname>Berthon</surname><given-names>A</given-names></name>, <name><surname>Syed</surname><given-names>A</given-names></name>, <name><surname>Yabe</surname><given-names>M</given-names></name>, <etal /> (<year>2020</year>). <article-title>Cancer therapy shapes the fitness landscape of clonal hematopoiesis</article-title>. <source>Nat. Genet</source>
<volume>52</volume>, <fpage>1219</fpage>&#8211;<lpage>1226</lpage>. <pub-id pub-id-type="doi">10.1038/s41588-020-00710-0</pub-id>.<pub-id pub-id-type="pmid">33106634</pub-id></mixed-citation>
      </ref>
      <ref id="R38">
        <label>38.</label>
        <mixed-citation publication-type="journal"><name><surname>Williamson</surname><given-names>SC</given-names></name>, <name><surname>Metcalf</surname><given-names>RL</given-names></name>, <name><surname>Trapani</surname><given-names>F</given-names></name>, <name><surname>Mohan</surname><given-names>S</given-names></name>, <name><surname>Antonello</surname><given-names>J</given-names></name>, <name><surname>Abbott</surname><given-names>B</given-names></name>, <name><surname>Leong</surname><given-names>HS</given-names></name>, <name><surname>Chester</surname><given-names>CPE</given-names></name>, <name><surname>Simms</surname><given-names>N</given-names></name>, <name><surname>Polanski</surname><given-names>R</given-names></name>, <etal /> (<year>2016</year>). <article-title>Vasculogenic mimicry in small cell lung cancer</article-title>. <source>Nat. Commun</source>
<volume>7</volume>, <fpage>13322</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms13322</pub-id>.<pub-id pub-id-type="pmid">27827359</pub-id></mixed-citation>
      </ref>
      <ref id="R39">
        <label>39.</label>
        <mixed-citation publication-type="journal"><name><surname>Lim</surname><given-names>JS</given-names></name>, <name><surname>Ibaseta</surname><given-names>A</given-names></name>, <name><surname>Fischer</surname><given-names>MM</given-names></name>, <name><surname>Cancilla</surname><given-names>B</given-names></name>, <name><surname>O&#8217;Young</surname><given-names>G</given-names></name>, <name><surname>Cristea</surname><given-names>S</given-names></name>, <name><surname>Luca</surname><given-names>VC</given-names></name>, <name><surname>Yang</surname><given-names>D</given-names></name>, <name><surname>Jahchan</surname><given-names>NS</given-names></name>, <name><surname>Hamard</surname><given-names>C</given-names></name>, <etal /> (<year>2017</year>). <article-title>Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer</article-title>. <source>Nature</source>
<volume>545</volume>, <fpage>360</fpage>&#8211;<lpage>364</lpage>. <pub-id pub-id-type="doi">10.1038/nature22323</pub-id>.<pub-id pub-id-type="pmid">28489825</pub-id></mixed-citation>
      </ref>
      <ref id="R40">
        <label>40.</label>
        <mixed-citation publication-type="journal"><name><surname>Gay</surname><given-names>CM</given-names></name>, <name><surname>Stewart</surname><given-names>CA</given-names></name>, <name><surname>Park</surname><given-names>EM</given-names></name>, <name><surname>Diao</surname><given-names>L</given-names></name>, <name><surname>Groves</surname><given-names>SM</given-names></name>, <name><surname>Heeke</surname><given-names>S</given-names></name>, <name><surname>Nabet</surname><given-names>BY</given-names></name>, <name><surname>Fujimoto</surname><given-names>J</given-names></name>, <name><surname>Solis</surname><given-names>LM</given-names></name>, <name><surname>Lu</surname><given-names>W</given-names></name>, <etal /> (<year>2021</year>). <article-title>Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities</article-title>. <source>Cancer Cell</source>
<volume>39</volume>, <fpage>346</fpage>&#8211;<lpage>360.e7</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2020.12.014</pub-id>.<pub-id pub-id-type="pmid">33482121</pub-id></mixed-citation>
      </ref>
      <ref id="R41">
        <label>41.</label>
        <mixed-citation publication-type="journal"><name><surname>Mahadevan</surname><given-names>NR</given-names></name>, <name><surname>Knelson</surname><given-names>EH</given-names></name>, <name><surname>Wolff</surname><given-names>JO</given-names></name>, <name><surname>Vajdi</surname><given-names>A</given-names></name>, <name><surname>Saig&#237;</surname><given-names>M</given-names></name>, <name><surname>Campisi</surname><given-names>M</given-names></name>, <name><surname>Hong</surname><given-names>D</given-names></name>, <name><surname>Thai</surname><given-names>TC</given-names></name>, <name><surname>Piel</surname><given-names>B</given-names></name>, <name><surname>Han</surname><given-names>S</given-names></name>, <etal /> (<year>2021</year>). <article-title>Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity</article-title>. <source>Cancer Discov</source>. <volume>11</volume>, <fpage>1952</fpage>&#8211;<lpage>1969</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0913</pub-id>.<pub-id pub-id-type="pmid">33707236</pub-id></mixed-citation>
      </ref>
      <ref id="R42">
        <label>42.</label>
        <mixed-citation publication-type="journal"><name><surname>Crino</surname><given-names>PB</given-names></name>, <name><surname>Nathanson</surname><given-names>KL</given-names></name>, and <name><surname>Henske</surname><given-names>EP</given-names></name> (<year>2006</year>). <article-title>The tuberous sclerosis complex</article-title>. <source>N. Engl. J. Med</source>
<volume>355</volume>, <fpage>1345</fpage>&#8211;<lpage>1356</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra055323</pub-id>.<pub-id pub-id-type="pmid">17005952</pub-id></mixed-citation>
      </ref>
      <ref id="R43">
        <label>43.</label>
        <mixed-citation publication-type="journal"><name><surname>Tapon</surname><given-names>N</given-names></name>, <name><surname>Ito</surname><given-names>N</given-names></name>, <name><surname>Dickson</surname><given-names>BJ</given-names></name>, <name><surname>Treisman</surname><given-names>JE</given-names></name>, and <name><surname>Hariharan</surname><given-names>IK</given-names></name> (<year>2001</year>). <article-title>The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation</article-title>. <source>Cell</source>
<volume>105</volume>, <fpage>345</fpage>&#8211;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(01)00332-4</pub-id>.<pub-id pub-id-type="pmid">11348591</pub-id></mixed-citation>
      </ref>
      <ref id="R44">
        <label>44.</label>
        <mixed-citation publication-type="journal"><name><surname>Garami</surname><given-names>A</given-names></name>, <name><surname>Zwartkruis</surname><given-names>FJT</given-names></name>, <name><surname>Nobukuni</surname><given-names>T</given-names></name>, <name><surname>Joaquin</surname><given-names>M</given-names></name>, <name><surname>Roccio</surname><given-names>M</given-names></name>, <name><surname>Stocker</surname><given-names>H</given-names></name>, <name><surname>Kozma</surname><given-names>SC</given-names></name>, <name><surname>Hafen</surname><given-names>E</given-names></name>, <name><surname>Bos</surname><given-names>JL</given-names></name>, and <name><surname>Thomas</surname><given-names>G</given-names></name> (<year>2003</year>). <article-title>Insulin activation of rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2</article-title>. <source>Mol. Cell</source>
<volume>11</volume>, <fpage>1457</fpage>&#8211;<lpage>1466</lpage>. <pub-id pub-id-type="doi">10.1016/S1097-2765(03)00220-X</pub-id>.<pub-id pub-id-type="pmid">12820960</pub-id></mixed-citation>
      </ref>
      <ref id="R45">
        <label>45.</label>
        <mixed-citation publication-type="journal"><name><surname>Brugarolas</surname><given-names>J</given-names></name>, <name><surname>Lei</surname><given-names>K</given-names></name>, <name><surname>Hurley</surname><given-names>RL</given-names></name>, <name><surname>Manning</surname><given-names>BD</given-names></name>, <name><surname>Reiling</surname><given-names>JH</given-names></name>, <name><surname>Hafen</surname><given-names>E</given-names></name>, <name><surname>Witters</surname><given-names>LA</given-names></name>, <name><surname>Ellisen</surname><given-names>LW</given-names></name>, and <name><surname>Kaelin</surname><given-names>WG</given-names></name> (<year>2004</year>). <article-title>Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex</article-title>. <source>Genes Dev</source>. <volume>18</volume>, <fpage>2893</fpage>&#8211;<lpage>2904</lpage>. <pub-id pub-id-type="doi">10.1101/gad.1256804</pub-id>.<pub-id pub-id-type="pmid">15545625</pub-id></mixed-citation>
      </ref>
      <ref id="R46">
        <label>46.</label>
        <mixed-citation publication-type="journal"><name><surname>Sivakumar</surname><given-names>S</given-names></name>, <name><surname>Moore</surname><given-names>JA</given-names></name>, <name><surname>Montesion</surname><given-names>M</given-names></name>, <name><surname>Sharaf</surname><given-names>R</given-names></name>, <name><surname>Lin</surname><given-names>DI</given-names></name>, <name><surname>Fleishmann</surname><given-names>Z</given-names></name>, <etal /> (<year>2022</year>). <article-title>Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation</article-title>. <source>Preprint at bioRxiv</source>. <pub-id pub-id-type="doi">10.1101/2022.07.27.501738</pub-id>.</mixed-citation>
      </ref>
      <ref id="R47">
        <label>47.</label>
        <mixed-citation publication-type="journal"><name><surname>Saito</surname><given-names>T</given-names></name>, <name><surname>Tsuta</surname><given-names>K</given-names></name>, <name><surname>Fukumoto</surname><given-names>KJ</given-names></name>, <name><surname>Matsui</surname><given-names>H</given-names></name>, <name><surname>Konobu</surname><given-names>T</given-names></name>, <name><surname>Torii</surname><given-names>Y</given-names></name>, <name><surname>Yokoi</surname><given-names>T</given-names></name>, <name><surname>Kurata</surname><given-names>T</given-names></name>, <name><surname>Kurokawa</surname><given-names>H</given-names></name>, <name><surname>Uemura</surname><given-names>Y</given-names></name>, <etal /> (<year>2017</year>). <article-title>Combined small cell lung carcinoma and giant cell carcinoma: a case report</article-title>. <source>Surg. Case Rep</source>
<volume>3</volume>, <fpage>52</fpage>. <pub-id pub-id-type="doi">10.1186/s40792-017-0328-9</pub-id>.<pub-id pub-id-type="pmid">28364180</pub-id></mixed-citation>
      </ref>
      <ref id="R48">
        <label>48.</label>
        <mixed-citation publication-type="journal"><name><surname>Ebisu</surname><given-names>Y</given-names></name>, <name><surname>Ishida</surname><given-names>M</given-names></name>, <name><surname>Saito</surname><given-names>T</given-names></name>, <name><surname>Murakawa</surname><given-names>T</given-names></name>, <name><surname>Uemura</surname><given-names>Y</given-names></name>, and <name><surname>Tsuta</surname><given-names>K</given-names></name> (<year>2018</year>). <article-title>Combined small cell carcinoma with giant cell carcinoma component of the lung: a case successfully diagnosed by computed tomography-guided fine-needle aspiration cytology</article-title>. <source>Oncol. Lett</source>
<volume>15</volume>, <fpage>1907</fpage>&#8211;<lpage>1911</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2017.7448</pub-id>.<pub-id pub-id-type="pmid">29399198</pub-id></mixed-citation>
      </ref>
      <ref id="R49">
        <label>49.</label>
        <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Ng</surname><given-names>SR</given-names></name>, <name><surname>Col&#243;n</surname><given-names>CI</given-names></name>, <name><surname>Drapkin</surname><given-names>BJ</given-names></name>, <name><surname>Hsu</surname><given-names>PP</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Nabel</surname><given-names>CS</given-names></name>, <name><surname>Lewis</surname><given-names>CA</given-names></name>, <name><surname>Romero</surname><given-names>R</given-names></name>, <name><surname>Mercer</surname><given-names>KL</given-names></name>, <etal /> (<year>2019</year>). <article-title>Identification of DHODH as a therapeutic target in small cell lung cancer</article-title>. <source>Sci. Transl. Med</source>
<volume>11</volume>, <fpage>eaaw7852</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aaw7852</pub-id>.<pub-id pub-id-type="pmid">31694929</pub-id></mixed-citation>
      </ref>
      <ref id="R50">
        <label>50.</label>
        <mixed-citation publication-type="journal"><name><surname>Pandya</surname><given-names>KJ</given-names></name>, <name><surname>Dahlberg</surname><given-names>S</given-names></name>, <name><surname>Hidalgo</surname><given-names>M</given-names></name>, <name><surname>Cohen</surname><given-names>RB</given-names></name>, <name><surname>Lee</surname><given-names>MW</given-names></name>, <name><surname>Schiller</surname><given-names>JH</given-names></name>, and <name><surname>Johnson</surname><given-names>DH</given-names></name>; <collab>Eastern Cooperative Oncology Group E1500</collab> (<year>2007</year>). <article-title>A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)</article-title>. <source>J. Thorac. Oncol</source>
<volume>2</volume>, <fpage>1036</fpage>&#8211;<lpage>1041</lpage>. <pub-id pub-id-type="doi">10.1097/JTO.0b013e318155a439</pub-id>.<pub-id pub-id-type="pmid">17975496</pub-id></mixed-citation>
      </ref>
      <ref id="R51">
        <label>51.</label>
        <mixed-citation publication-type="journal"><name><surname>Tarhini</surname><given-names>A</given-names></name>, <name><surname>Kotsakis</surname><given-names>A</given-names></name>, <name><surname>Gooding</surname><given-names>W</given-names></name>, <name><surname>Shuai</surname><given-names>Y</given-names></name>, <name><surname>Petro</surname><given-names>D</given-names></name>, <name><surname>Friedland</surname><given-names>D</given-names></name>, <name><surname>Belani</surname><given-names>CP</given-names></name>, <name><surname>Dacic</surname><given-names>S</given-names></name>, and <name><surname>Argiris</surname><given-names>A</given-names></name> (<year>2010</year>). <article-title>Phase II study of everolimus (RAD001)in previously treated small cell lung cancer</article-title>. <source>Clin. Cancer Res</source>
<volume>16</volume>, <fpage>5900</fpage>&#8211;<lpage>5907</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-0802</pub-id>.<pub-id pub-id-type="pmid">21045083</pub-id></mixed-citation>
      </ref>
      <ref id="R52">
        <label>52.</label>
        <mixed-citation publication-type="journal"><name><surname>Kern</surname><given-names>JA</given-names></name>, <name><surname>Kim</surname><given-names>J</given-names></name>, <name><surname>Foster</surname><given-names>DG</given-names></name>, <name><surname>Mishra</surname><given-names>R</given-names></name>, <name><surname>Gardner</surname><given-names>EE</given-names></name>, <name><surname>Poirier</surname><given-names>JT</given-names></name>, <name><surname>Rivard</surname><given-names>C</given-names></name>, <name><surname>Yu</surname><given-names>H</given-names></name>, <name><surname>Finigan</surname><given-names>JH</given-names></name>, <name><surname>Dowlati</surname><given-names>A</given-names></name>, <etal /> (<year>2020</year>). <article-title>Role of mTOR as an essential kinase in SCLC</article-title>. <source>J. Thorac. Oncol</source>
<volume>15</volume>, <fpage>1522</fpage>&#8211;<lpage>1534</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtho.2020.05.026</pub-id>.<pub-id pub-id-type="pmid">32599072</pub-id></mixed-citation>
      </ref>
      <ref id="R53">
        <label>53.</label>
        <mixed-citation publication-type="journal"><name><surname>Sakre</surname><given-names>N</given-names></name>, <name><surname>Wildey</surname><given-names>G</given-names></name>, <name><surname>Behtaj</surname><given-names>M</given-names></name>, <name><surname>Kresak</surname><given-names>A</given-names></name>, <name><surname>Yang</surname><given-names>M</given-names></name>, <name><surname>Fu</surname><given-names>P</given-names></name>, and <name><surname>Dowlati</surname><given-names>A</given-names></name> (<year>2017</year>). <article-title>RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR</article-title>. <source>Oncotarget</source>
<volume>8</volume>, <fpage>5992</fpage>&#8211;<lpage>6002</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.13362</pub-id>.<pub-id pub-id-type="pmid">27863413</pub-id></mixed-citation>
      </ref>
      <ref id="R54">
        <label>54.</label>
        <mixed-citation publication-type="journal"><name><surname>Gardner</surname><given-names>EE</given-names></name>, <name><surname>Connis</surname><given-names>N</given-names></name>, <name><surname>Poirier</surname><given-names>JT</given-names></name>, <name><surname>Cope</surname><given-names>L</given-names></name>, <name><surname>Dobromilskaya</surname><given-names>I</given-names></name>, <name><surname>Gallia</surname><given-names>GL</given-names></name>, <name><surname>Rudin</surname><given-names>CM</given-names></name>, and <name><surname>Hann</surname><given-names>CL</given-names></name> (<year>2014</year>). <article-title>Rapamycin rescues ABT-737 efficacy in small cell lung cancer</article-title>. <source>Cancer Res</source>. <volume>74</volume>, <fpage>2846</fpage>&#8211;<lpage>2856</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-3460</pub-id>.<pub-id pub-id-type="pmid">24614082</pub-id></mixed-citation>
      </ref>
      <ref id="R55">
        <label>55.</label>
        <mixed-citation publication-type="journal"><name><surname>Sen</surname><given-names>T</given-names></name>, <name><surname>Tong</surname><given-names>P</given-names></name>, <name><surname>Diao</surname><given-names>L</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Fan</surname><given-names>Y</given-names></name>, <name><surname>Hoff</surname><given-names>J</given-names></name>, <name><surname>Heymach</surname><given-names>JV</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, and <name><surname>Byers</surname><given-names>LA</given-names></name> (<year>2017</year>). <article-title>Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer</article-title>. <source>Clin. Cancer Res</source>
<volume>23</volume>, <fpage>6239</fpage>&#8211;<lpage>6253</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-1284</pub-id>.<pub-id pub-id-type="pmid">28698200</pub-id></mixed-citation>
      </ref>
      <ref id="R56">
        <label>56.</label>
        <mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>SC</given-names></name>, <name><surname>Wei</surname><given-names>Y</given-names></name>, <name><surname>Luo</surname><given-names>X</given-names></name>, <name><surname>Jia</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Gopal</surname><given-names>P</given-names></name>, <name><surname>Zhu</surname><given-names>M</given-names></name>, <name><surname>Nassour</surname><given-names>I</given-names></name>, <name><surname>Chuang</surname><given-names>J-C</given-names></name>, <etal /> (<year>2017</year>). <article-title>Arid1a has context-dependent oncogenic and tumor suppressor functions in liver cancer</article-title>. <source>Cancer Cell</source>
<volume>32</volume>, <fpage>574</fpage>&#8211;<lpage>589.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2017.10.007</pub-id>.<pub-id pub-id-type="pmid">29136504</pub-id></mixed-citation>
      </ref>
      <ref id="R57">
        <label>57.</label>
        <mixed-citation publication-type="journal"><name><surname>Sen</surname><given-names>T</given-names></name>, <name><surname>Rodriguez</surname><given-names>BL</given-names></name>, <name><surname>Chen</surname><given-names>L</given-names></name>, <name><surname>Corte</surname><given-names>CMD</given-names></name>, <name><surname>Morikawa</surname><given-names>N</given-names></name>, <name><surname>Fujimoto</surname><given-names>J</given-names></name>, <name><surname>Cristea</surname><given-names>S</given-names></name>, <name><surname>Nguyen</surname><given-names>T</given-names></name>, <name><surname>Diao</surname><given-names>L</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <etal /> (<year>2019</year>). <article-title>Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer</article-title>. <source>Cancer Discov</source>. <volume>9</volume>, <fpage>646</fpage>&#8211;<lpage>661</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-1020</pub-id>.<pub-id pub-id-type="pmid">30777870</pub-id></mixed-citation>
      </ref>
      <ref id="R58">
        <label>58.</label>
        <mixed-citation publication-type="journal"><name><surname>Stewart</surname><given-names>SA</given-names></name>, <name><surname>Dykxhoorn</surname><given-names>DM</given-names></name>, <name><surname>Palliser</surname><given-names>D</given-names></name>, <name><surname>Mizuno</surname><given-names>H</given-names></name>, <name><surname>Yu</surname><given-names>EY</given-names></name>, <name><surname>An</surname><given-names>DS</given-names></name>, <name><surname>Sabatini</surname><given-names>DM</given-names></name>, <name><surname>Chen</surname><given-names>ISY</given-names></name>, <name><surname>Hahn</surname><given-names>WC</given-names></name>, <name><surname>Sharp</surname><given-names>PA</given-names></name>, <etal /> (<year>2003</year>). <article-title>Lentivirus-delivered stable gene silencing by RNAi in primary cells</article-title>. <source>RNA N. Y. N</source>
<volume>9</volume>, <fpage>493</fpage>&#8211;<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1261/rna.2192803</pub-id>.</mixed-citation>
      </ref>
      <ref id="R59">
        <label>59.</label>
        <mixed-citation publication-type="journal"><name><surname>Chiou</surname><given-names>S-H</given-names></name>, <name><surname>Winters</surname><given-names>IP</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Naranjo</surname><given-names>S</given-names></name>, <name><surname>Dudgeon</surname><given-names>C</given-names></name>, <name><surname>Tamburini</surname><given-names>FB</given-names></name>, <name><surname>Brady</surname><given-names>JJ</given-names></name>, <name><surname>Yang</surname><given-names>D</given-names></name>, <name><surname>Gr&#252;ner</surname><given-names>BM</given-names></name>, <name><surname>Chuang</surname><given-names>C-H</given-names></name>, <etal /> (<year>2015</year>). <article-title>Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing</article-title>. <source>Genes Dev</source>. <volume>29</volume>, <fpage>1576</fpage>&#8211;<lpage>1585</lpage>. <pub-id pub-id-type="doi">10.1101/gad.264861.115</pub-id>.<pub-id pub-id-type="pmid">26178787</pub-id></mixed-citation>
      </ref>
      <ref id="R60">
        <label>60.</label>
        <mixed-citation publication-type="journal"><name><surname>Cai</surname><given-names>H</given-names></name>, <name><surname>Chew</surname><given-names>SK</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Tsai</surname><given-names>MK</given-names></name>, <name><surname>Andrejka</surname><given-names>L</given-names></name>, <name><surname>Murray</surname><given-names>CW</given-names></name>, <name><surname>Hughes</surname><given-names>NW</given-names></name>, <name><surname>Shuldiner</surname><given-names>EG</given-names></name>, <name><surname>Ashkin</surname><given-names>EL</given-names></name>, <name><surname>Tang</surname><given-names>R</given-names></name>, <etal /> (<year>2021</year>). <article-title>A functional taxonomy of tumor suppression in oncogenic KRAS-driven lung cancer</article-title>. <source>Cancer Discov</source>. <volume>11</volume>, <fpage>1754</fpage>&#8211;<lpage>1773</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290</pub-id>.<pub-id pub-id-type="pmid">33608386</pub-id></mixed-citation>
      </ref>
      <ref id="R61">
        <label>61.</label>
        <mixed-citation publication-type="journal"><name><surname>Chaikovsky</surname><given-names>AC</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Jeng</surname><given-names>EE</given-names></name>, <name><surname>Loebell</surname><given-names>S</given-names></name>, <name><surname>Lee</surname><given-names>MC</given-names></name>, <name><surname>Murray</surname><given-names>CW</given-names></name>, <name><surname>Cheng</surname><given-names>R</given-names></name>, <name><surname>Demeter</surname><given-names>J</given-names></name>, <name><surname>Swaney</surname><given-names>DL</given-names></name>, <name><surname>Chen</surname><given-names>S-H</given-names></name>, <etal /> (<year>2021</year>). <article-title>The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D</article-title>. <source>Nature</source>
<volume>592</volume>, <fpage>794</fpage>&#8211;<lpage>798</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03474-7</pub-id>.<pub-id pub-id-type="pmid">33854239</pub-id></mixed-citation>
      </ref>
      <ref id="R62">
        <label>62.</label>
        <mixed-citation publication-type="journal"><name><surname>Tang</surname><given-names>R</given-names></name>, <name><surname>Shuldiner</surname><given-names>EG</given-names></name>, <name><surname>Kelly</surname><given-names>M</given-names></name>, <name><surname>Murray</surname><given-names>CW</given-names></name>, <name><surname>Hebert</surname><given-names>JD</given-names></name>, <name><surname>Andrejka</surname><given-names>L</given-names></name>, <name><surname>Tsai</surname><given-names>MK</given-names></name>, <name><surname>Hughes</surname><given-names>NW</given-names></name>, <name><surname>Parker</surname><given-names>MI</given-names></name>, <name><surname>Cai</surname><given-names>H</given-names></name>, <etal /> (<year>2021</year>). <article-title>Multiplexed identification of RAS paralog imbalance as a driver of lung cancer growth</article-title>. <source>Preprint at bioRxiv</source>. <pub-id pub-id-type="doi">10.1101/2021.07.08.451571</pub-id>.</mixed-citation>
      </ref>
      <ref id="R63">
        <label>63.</label>
        <mixed-citation publication-type="journal"><name><surname>Schindelin</surname><given-names>J</given-names></name>, <name><surname>Arganda-Carreras</surname><given-names>I</given-names></name>, <name><surname>Frise</surname><given-names>E</given-names></name>, <name><surname>Kaynig</surname><given-names>V</given-names></name>, <name><surname>Longair</surname><given-names>M</given-names></name>, <name><surname>Pietzsch</surname><given-names>T</given-names></name>, <name><surname>Preibisch</surname><given-names>S</given-names></name>, <name><surname>Rueden</surname><given-names>C</given-names></name>, <name><surname>Saalfeld</surname><given-names>S</given-names></name>, <name><surname>Schmid</surname><given-names>B</given-names></name>, <etal /> (<year>2012</year>). <article-title>Fiji: an open-source platform for biological-image analysis</article-title>. <source>Nat. Methods</source>
<volume>9</volume>, <fpage>676</fpage>&#8211;<lpage>682</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id>.<pub-id pub-id-type="pmid">22743772</pub-id></mixed-citation>
      </ref>
      <ref id="R64">
        <label>64.</label>
        <mixed-citation publication-type="journal"><name><surname>Patro</surname><given-names>R</given-names></name>, <name><surname>Duggal</surname><given-names>G</given-names></name>, <name><surname>Love</surname><given-names>MI</given-names></name>, <name><surname>Irizarry</surname><given-names>RA</given-names></name>, and <name><surname>Kingsford</surname><given-names>C</given-names></name> (<year>2017</year>). <article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title>. <source>Nat. Methods</source>
<volume>14</volume>, <fpage>417</fpage>&#8211;<lpage>419</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.4197</pub-id>.<pub-id pub-id-type="pmid">28263959</pub-id></mixed-citation>
      </ref>
      <ref id="R65">
        <label>65.</label>
        <mixed-citation publication-type="journal"><name><surname>Love</surname><given-names>MI</given-names></name>, <name><surname>Huber</surname><given-names>W</given-names></name>, and <name><surname>Anders</surname><given-names>S</given-names></name> (<year>2014</year>). <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol</source>. <volume>15</volume>, <fpage>550</fpage>. <pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id>.<pub-id pub-id-type="pmid">25516281</pub-id></mixed-citation>
      </ref>
      <ref id="R66">
        <label>66.</label>
        <mixed-citation publication-type="journal"><name><surname>Bindea</surname><given-names>G</given-names></name>, <name><surname>Mlecnik</surname><given-names>B</given-names></name>, <name><surname>Hackl</surname><given-names>H</given-names></name>, <name><surname>Charoentong</surname><given-names>P</given-names></name>, <name><surname>Tosolini</surname><given-names>M</given-names></name>, <name><surname>Kirilovsky</surname><given-names>A</given-names></name>, <name><surname>Fridman</surname><given-names>W-H</given-names></name>, <name><surname>Pag&#232;s</surname><given-names>F</given-names></name>, <name><surname>Trajanoski</surname><given-names>Z</given-names></name>, and <name><surname>Galon</surname><given-names>J</given-names></name> (<year>2009</year>). <article-title>ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks</article-title>. <source>Bioinformatics</source>
<volume>25</volume>, <fpage>1091</fpage>&#8211;<lpage>1093</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp101</pub-id>.<pub-id pub-id-type="pmid">19237447</pub-id></mixed-citation>
      </ref>
      <ref id="R67">
        <label>67.</label>
        <mixed-citation publication-type="journal"><name><surname>Shannon</surname><given-names>P</given-names></name>, <name><surname>Markiel</surname><given-names>A</given-names></name>, <name><surname>Ozier</surname><given-names>O</given-names></name>, <name><surname>Baliga</surname><given-names>NS</given-names></name>, <name><surname>Wang</surname><given-names>JT</given-names></name>, <name><surname>Ramage</surname><given-names>D</given-names></name>, <name><surname>Amin</surname><given-names>N</given-names></name>, <name><surname>Schwikowski</surname><given-names>B</given-names></name>, and <name><surname>Ideker</surname><given-names>T</given-names></name> (<year>2003</year>). <article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>. <source>Genome Res</source>. <volume>13</volume>, <fpage>2498</fpage>&#8211;<lpage>2504</lpage>. <pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>.<pub-id pub-id-type="pmid">14597658</pub-id></mixed-citation>
      </ref>
      <ref id="R68">
        <label>68.</label>
        <mixed-citation publication-type="journal"><name><surname>DuPage</surname><given-names>M</given-names></name>, <name><surname>Dooley</surname><given-names>AL</given-names></name>, and <name><surname>Jacks</surname><given-names>T</given-names></name> (<year>2009</year>). <article-title>Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase</article-title>. <source>Nat. Protoc</source>
<volume>4</volume>, <fpage>1064</fpage>&#8211;<lpage>1072</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2009.95</pub-id>.<pub-id pub-id-type="pmid">19561589</pub-id></mixed-citation>
      </ref>
      <ref id="R69">
        <label>69.</label>
        <mixed-citation publication-type="journal"><name><surname>Meyers</surname><given-names>RM</given-names></name>, <name><surname>Bryan</surname><given-names>JG</given-names></name>, <name><surname>McFarland</surname><given-names>JM</given-names></name>, <name><surname>Weir</surname><given-names>BA</given-names></name>, <name><surname>Sizemore</surname><given-names>AE</given-names></name>, <name><surname>Xu</surname><given-names>H</given-names></name>, <name><surname>Dharia</surname><given-names>NV</given-names></name>, <name><surname>Montgomery</surname><given-names>PG</given-names></name>, <name><surname>Cowley</surname><given-names>GS</given-names></name>, <name><surname>Pantel</surname><given-names>S</given-names></name>, <etal /> (<year>2017</year>). <article-title>Computational correction of copy number effect improves specificity of CRISPR&#8211;Cas9 essentiality screens in cancer cells</article-title>. <source>Nat. Genet</source>
<volume>49</volume>, <fpage>1779</fpage>&#8211;<lpage>1784</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3984</pub-id>.<pub-id pub-id-type="pmid">29083409</pub-id></mixed-citation>
      </ref>
      <ref id="R70">
        <label>70.</label>
        <mixed-citation publication-type="journal"><name><surname>Dempster</surname><given-names>JM</given-names></name>, <name><surname>Rossen</surname><given-names>J</given-names></name>, <name><surname>Kazachkova</surname><given-names>M</given-names></name>, <name><surname>Pan</surname><given-names>J</given-names></name>, <name><surname>Kugener</surname><given-names>G</given-names></name>, <name><surname>Root</surname><given-names>DE</given-names></name>, and <name><surname>Tsherniak</surname><given-names>A</given-names></name> (<year>2019</year>). <article-title>Extracting biological insights from the project achilles genome-scale CRISPR screens in cancer cell lines</article-title>. <source>Preprint at bioRxiv</source>. <pub-id pub-id-type="doi">10.1101/720243</pub-id>.</mixed-citation>
      </ref>
      <ref id="R71">
        <label>71.</label>
        <mixed-citation publication-type="journal"><collab>AACR Project GENIE Consortium</collab> (<year>2017</year>). <article-title>AACR project GENIE: powering precision medicine through an international Consortium</article-title>. <source>Cancer Discov</source>. <volume>7</volume>, <fpage>818</fpage>&#8211;<lpage>831</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0151</pub-id>.<pub-id pub-id-type="pmid">28572459</pub-id></mixed-citation>
      </ref>
      <ref id="R72">
        <label>72.</label>
        <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Lin</surname><given-names>W-Y</given-names></name>, <name><surname>Rizvi</surname><given-names>H</given-names></name>, <name><surname>Cai</surname><given-names>H</given-names></name>, <name><surname>McFarland</surname><given-names>CD</given-names></name>, <name><surname>Rogers</surname><given-names>ZN</given-names></name>, <name><surname>Yousefi</surname><given-names>M</given-names></name>, <name><surname>Winters</surname><given-names>IP</given-names></name>, <name><surname>Rudin</surname><given-names>CM</given-names></name>, <name><surname>Petrov</surname><given-names>DA</given-names></name>, and <name><surname>Winslow</surname><given-names>MM</given-names></name> (<year>2021</year>). <article-title>Quantitative in vivo analyses reveal a complex pharmacogenomic landscape in lung adenocarcinoma</article-title>. <source>Cancer Res</source>. <volume>81</volume>, <fpage>4570</fpage>&#8211;<lpage>4580</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-21-0716</pub-id>.<pub-id pub-id-type="pmid">34215621</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig position="float" id="F1">
      <label>Figure 1.</label>
      <caption>
        <title>Naphthalene treatment enhances SCLC tumor development upon lentiviral Cre delivery</title>
        <p id="P66">(A) Workflow diagram for lentiviral Cre delivery (Lenti-Cre) used to generate SCLC in mice.</p>
        <p id="P67">(B) Representative H&amp;E staining of lung sections (with some intestine in the middle panel) from mice transduced with Ad-CMV-Cre (Ad-Cre) or HIV-PGK-Cre (Lenti-Cre) alone (NT) or following corn oil (vehicle [veh.]) or naphthalene (naph.) pre-treatment as in (A). Scale bar, 2 mm.</p>
        <p id="P68">(C) Quantification of tumor burden and numbers from mice in (B) (n = 1 experiment, with n = 3 or 4 mice per condition). p values were calculated using one-way ANOVA with post-hoc Tukey test. *p &lt; 0.05 and **p &lt; 0.01.</p>
        <p id="P69">(D) Representative H&amp;E and immunohistochemistry (IHC) staining (brown signal) images of lung sections from mice transduced with HIV-PGK-Cre (Lenti-Cre) or Ad-CMV-Cre (Ad-Cre) as a control. Scale bar, 100 &#956;m. Higher magnification images are shown in insets, where scale bar indicates 50 &#956;m.</p>
        <p id="P70">(E) Frequencies of CC10<sup>high</sup> versus CC10<sup>low</sup> tumors quantified from images of lung sections from mice transduced with HIV-PGK-Cre (Lenti-Cre) as in (D) (n = 2 mice). The analyses of tumors from mice infected with Ad-CMV-Cre (Ad-Cre) and Ad-cGRP-Cre are derived from data available in Yang et al. (2018).<sup><xref rid="R26" ref-type="bibr">26</xref></sup></p>
        <p id="P71">(F and G) Bar graphs of RNA expression of selected genes (RNA-seq) in SCLC cell lines (Naph. + Lenti-Cre, n = 1; Lenti-Cre, n = 1; Naph. + Ad-CMV-Cre, n = 1; Ad-CMV-Cre, n = 2) (Lenti-Cre: HIV-PGK-Cre). (F) Genes representing the four major SCLC subtypes. (G) Common neuroendocrine markers. Data represented as mean &#177; SEM (C) or mean &#177; SD (F and G).</p>
      </caption>
      <graphic ns1:href="nihms-1872761-f0002" position="float" />
    </fig>
    <fig position="float" id="F2">
      <label>Figure 2.</label>
      <caption>
        <title>A meta-analysis of genetic studies identifies candidate drivers of SCLC development</title>
        <p id="P72">(A) Diagram of the meta-analysis workflow.</p>
        <p id="P73">(B) Total number of genes represented when cutoff criteria are applied on total patient number (e.g., 2 genes were profiled in &#8805;2,000 patients, ~100 genes were profiled in &#8805;1,100 patients).</p>
        <p id="P74">(C) Alteration frequencies of top 25 gene candidates in all available patient data profiled.</p>
        <p id="P75">(D) Top 10 enriched pathways for genes altered in &#8805;3% of SCLC patients, were profiled in at least 250 patients and coded for protein with amino acid residue length of &#8804;2,000. Changing the gene cutoff criteria (e.g., removing amino acid residue length limits on protein products and keeping only genes that are expressed at &#8805;5 reads per kilobase of exon per million reads mapped [RPKM] in human SCLC) did not strongly affect the pathway enrichments. WikiPathways was used for enrichment analysis, with the word &#8220;pathways&#8221; removed in the figure for space considerations.</p>
        <p id="P76">(E) Diagram of selected SCLC driver candidates placed in signaling pathways on the basis of (D). <italic toggle="yes">RB1</italic> and <italic toggle="yes">TP53</italic> were not represented to highlight other candidate drivers. Fill color indicates percentage of patients with alterations in that gene. p value was determined using Bonferroni step-down correction on two-sided hypergeometric test (D).</p>
      </caption>
      <graphic ns1:href="nihms-1872761-f0003" position="float" />
    </fig>
    <fig position="float" id="F3">
      <label>Figure 3.</label>
      <caption>
        <title><italic toggle="yes">In vivo</italic> CRISPR screen uncovers both positive and negative effects of gene inactivation on SCLC growth and initiation</title>
        <p id="P77">(A) Diagram of the Tuba-seq workflow (n = 4 independent experimental pools, n = 3&#8211;22 mice per group).</p>
        <p id="P78">(B) Lung fluorescence images from mice transduced with pool 1. tdTomato fluorescence and bright-field images were merged. Scale bar, 1 mm.</p>
        <p id="P79">(C) Lung weights of mice (n = 3&#8211;5 per group) transduced with pool 1 at the time of collection.</p>
        <p id="P80">(D) Log-normal mean tumor size (normalized to tumors with sgInerts) for each putative tumor suppressor gene targeting sgRNA in <italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic> mice. For each gene, each circle represents a unique sgRNA. p values are indicated with a color code.</p>
        <p id="P81">(E) Tumor numbers (normalized to tumors with sgInerts as well as tumors in <italic toggle="yes">RPR2T</italic> mice for pools #1, 3 and 4 or <italic toggle="yes">RPR2L</italic> mice for pool #2) for each putative tumor suppressor gene targeting sgRNA in <italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic> mice. For each gene, each circle represents a unique sgRNA. p values are indicated with a color code.</p>
        <p id="P82">The 95% confidence intervals were calculated using bootstrapping (D and E). p values were determined using two-sided unpaired t test (C) or bootstrapping followed by Benjamini-Hochberg correction (D and E). Data are represented as mean &#177; SEM (C) or mean &#177; 95% confidence interval (D and E). ns, not significant.</p>
      </caption>
      <graphic ns1:href="nihms-1872761-f0004" position="float" />
    </fig>
    <fig position="float" id="F4">
      <label>Figure 4.</label>
      <caption>
        <title>TSC1 is a tumor suppressor in mouse SCLC</title>
        <p id="P83">(A) Representative H&amp;E sections of lungs (and spleen and intestine) from <italic toggle="yes">RPR2T</italic> and <italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic> mice transduced with Lenti-sg<italic toggle="yes">Tsc1</italic>/Cre sgRNA 1 (Lenti-sg<italic toggle="yes">Tsc1</italic>-1/Cre) or Lenti-sg<italic toggle="yes">Tsc1</italic>/Cre sgRNA2 (Lenti-sg<italic toggle="yes">Tsc1</italic>-2/Cre) (n = 2 independent experiments, n = 2&#8211;6 mice per group). Mice were collected 18 weeks after transduction. Scale bar, 2 mm.</p>
        <p id="P84">(B) Quantification of tumor size and number in (A).</p>
        <p id="P85">(C) Representative H&amp;E and immunohistochemistry (IHC) staining (brown signal) images of lung sections from mice transduced with Lenti-sg<italic toggle="yes">Tsc1</italic>-1/Cre or Lenti-sg<italic toggle="yes">Tsc1</italic>-2/Cre. Scale bar, 100 &#956;m.</p>
        <p id="P86">(D) Immunoassay of TSC1, S6, and phosphorylated S6 (p-S6) in cell lines derived from <italic toggle="yes">Tsc1</italic>-wild-type (WT) and <italic toggle="yes">Tsc1</italic>-knockout (KO) mouse tumors. Overexposed image is shown to confirm the knockout. HSP90 was used as a loading control.</p>
        <p id="P87">(E) Quantification of TSC1 and phosphorylated S6 (p-S6) expression from (D). Values were normalized to <italic toggle="yes">Tsc1</italic>-WT cell lines.</p>
        <p id="P88">(F) IC<sub>50</sub> values of cell lines derived from <italic toggle="yes">Tsc1</italic>-wild-type (WT) and <italic toggle="yes">Tsc1</italic>-knockout (KO) mouse tumors with the mTOR inhibitor AZD8055.</p>
        <p id="P89">(G) Proliferation curves of mouse SCLC lines following transduction with Lenti-EFS-EGFP-T2A-Bsd (EGFP-Bsd) or Lenti-EFS-hTSC1-T2A-Bsd (hTSC1-Bsd) lentiviruses, as indicated. Exponential (Malthusian) growth least squares fit was used to model growth curves.</p>
        <p id="P90">p values were determined using two-sided unpaired t test (B, E, and F) or extra sum-of-squares F test (G). Data are represented as mean &#177; SEM (B), mean &#177; SD for n = 3 or 4 cell lines derived from independent tumors (E), mean &#177; SEM for IC<sub>50</sub> values calculated from n = 3&#8211;8 biological replicates with n = 3 technical replicates (F), or mean &#177; SD for a representative experiment from n = 2 biological replicates with n = 3 technical replicates (G). ns, not significant. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, and ****p &lt; 0.0001.</p>
      </caption>
      <graphic ns1:href="nihms-1872761-f0005" position="float" />
    </fig>
    <fig position="float" id="F5">
      <label>Figure 5.</label>
      <caption>
        <title>TSC1 is a tumor suppressor in human SCLC</title>
        <p id="P91">(A) Schematic of the pool competition assay (n = 1 experiment with n = 3 technical replicates) using epitope-tagged (EpicTag) NCI-H82 cells.</p>
        <p id="P92">(B) Stacked bar plot of percentage representation of epitope-labeled populations on days 7, 14, and 21. Day 0 sample was unavailable. Statistical significance indicated next to epitope tags represent comparisons between days 7 and 14, days 7 and 21, and days 14 and 21.</p>
        <p id="P93">(C) Modal distribution of phosphorylated S6 (p-S6) signal across the different epitope-labeled populations. Percentage values represent the proportion of p-S6-high population. One representative experimental replicate from day 21 is shown; all other replicates across days exhibit similar p-S6 signal distribution to what is shown.</p>
        <p id="P94">(D) Immunoassay of TSC1-mTOR pathway members in human SCLC cell lines. Graph shows the ratio of p-S6 to S6 signal following normalization to HSP90 loading control.</p>
        <p id="P95">(E) Growth curves of human SCLC lines following transduction with Lenti-EFS-EGFP-T2A-Bsd (EGFP-Bsd) or Lenti-EFS-hTSC1-T2A-Bsd (hTSC1-Bsd) lenti-viruses. NCI-H446 hTSC1-Bsd cells never reached sufficient numbers for plating post-transduction and selection.</p>
        <p id="P96">Data are represented as mean &#177; SD for a representative experiment out of n = 2 biological replicates (B), a representative experiment (D), or n = 3 (E) biological replicates with n = 3 technical replicates. Exponential (Malthusian) growth least squares fit was used to model growth curves in (E). p values were determined using repeated measures two-way ANOVA with Geisser-Greenhouse correction followed by post-hoc Tukey test (B) or extra sum-of-squares F test (E). ns, not significant. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, and ****p &lt; 0.0001.</p>
      </caption>
      <graphic ns1:href="nihms-1872761-f0006" position="float" />
    </fig>
    <table-wrap position="float" id="T1">
      <caption>
        <p id="P97">KEY RESOURCES TABLE</p>
      </caption>
      <table frame="hsides" rules="groups">
        <colgroup span="1">
          <col align="left" valign="middle" span="1" />
          <col align="left" valign="middle" span="1" />
          <col align="left" valign="middle" span="1" />
        </colgroup>
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">REAGENT or RESOURCE</th>
            <th align="left" valign="top" rowspan="1" colspan="1">SOURCE</th>
            <th align="left" valign="top" rowspan="1" colspan="1">IDENTIFIER</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="3" align="left" valign="top" style="border-bottom: solid 1px" rowspan="1">Antibodies</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Antibodies for CyTOF, please see <xref rid="SD2" ref-type="supplementary-material">Table S8</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">ImmPRESS HRP Horse anti-Rabbit IgG</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Vector Laboratories</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#MP-7401; RRID:AB_2336529</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">ImmPRESS HRP Horse anti-Mouse IgG</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Vector Laboratories</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#MP-7402</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Alexa Fluor 594 Donkey anti-Goat IgG (H + L) Cross-Adsorbed Secondary Antibody</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#A11058; RRID:AB_2534105</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Alexa Fluor 488 Donkey anti-Rabbit IgG (H + L) Highly Cross-Adsorbed Secondary Antibody</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#A-21206; RRID:AB_2535792</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-RFP Pre-adsorbed Polyclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Rockland</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#600-401-379; RRID:AB_2209751</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Goat anti-RFP Polyclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">MyBioSource</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#MBS448122</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse anti-Uteroglobin/SCGB1A1/CC10 (E&#8211;11) Monoclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Santa Cruz Biotechnology</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#sc-365992; RRID:AB_10915481</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-HES1 (D6P2U) Monoclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#11988; RRID:AB_2728766</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-NEUROD1 [EPR4008] Monoclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Abcam</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#ab109224; RRID:AB_10861489</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-UCHL1 Polyclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#HPA005993; RRID:AB_1858560</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-phospho-S6 (Ser235/236) Polyclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#2211, RRID:AB_331679</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-S6 (5G10) Monoclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#2217; RRID:AB_331355</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-phospho-4E-BP1 (Ser65) Polyclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#9451; RRID:AB_330947</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-4E-BP1 Monoclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#9644; RRID:AB_2097841</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-GFP (D5.1) Monoclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#2956; RRID:AB_1196615</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-p-mTOR (Ser2448) (D9C2) Monoclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#5536; RRID:AB_10691552</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-mTOR Polyclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#2972; RRID:AB_330978</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse anti-MASH1 Monoclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">BD Biosciences</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#556604; RRID:AB_396479</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-HSP90 (C45G5) Monoclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#4877; RRID:AB_2233307</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-TSC1 (D43E2) Monoclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#6935; RRID:AB_10860420</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rabbit anti-TSC2 (D93F12) Monoclonal</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#4308; RRID:AB_10547134</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" style="border-bottom: solid 1px; border-top: solid 1px" rowspan="1">Bacterial and virus strains</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Ad5-CMV-Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">University of Iowa</td>
            <td align="left" valign="top" rowspan="1" colspan="1">VVC-U of Iowa-5</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Ad5-CMV-eGFP</td>
            <td align="left" valign="top" rowspan="1" colspan="1">University of Iowa</td>
            <td align="left" valign="top" rowspan="1" colspan="1">VVC-U of Iowa-4</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">FIV-CMV-Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">University of Iowa</td>
            <td align="left" valign="top" rowspan="1" colspan="1">VVC-U of Iowa-28</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" style="border-bottom: solid 1px; border-top: solid 1px" rowspan="1">Chemicals, peptides, and recombinant proteins</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Naphthalene</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#184500</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">RPMI 1640</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Corning</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#15-040-CV</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Bovine Growth Serum</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#SH3054103HI</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Penicillin-Streptomycin-Glutamine</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Gibco</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#10378&#8211;016</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Dulbecco&#8217;s Modified Eagle Medium High-Glucose</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Gibco</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#11965&#8211;118</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Fetal Bovine Serum</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Omega Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#FB-01</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">AZD8055</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Selleckchem</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#S1555</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">alamarBlue<sup>&#8482;</sup> Cell Viability Reagent</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Invitrogen</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#DAL1100</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Blasticidin S HCL (10 mg/mL)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Gibco</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#A1113903</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Alt-R S.p. Cas9</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Integrated DNA Technologies</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#1081059</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Dimethyl sulfoxide (DMSO)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#BP231</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Saponin</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#84510</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Bovine Serum Albumin (BSA)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#B14</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">NaN<sub>3</sub></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Fisher Scientific</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#MP210289110</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Sodium butyrate</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#B5587-5G</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" style="border-bottom: solid 1px; border-top: solid 1px" rowspan="1">Critical commercial assays</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">SE buffer</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Lonza</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#V4XC-1032</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Lonza 4D-Nucleofector Unit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Lonza</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#AAF-1002X</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">MAXPAR X8 Multimetal Labeling Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Fluidigm</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#201300</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Cell-ID Intercalator-Ir</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Fluidigm</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#201192B</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Four Element Calibration Beads</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Fluidigm</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#201078</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Antigen Unmasking Solution, Citrate-Based</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Vector Laboratories</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#H-3300; RRID:AB_2336226</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">DAB Substrate Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Vector Laboratories</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#SK-4100; RRID:AB_2336382</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">ImmPRESS Excel Amplified Polymer Staining Kit, Anti-Rabbit IgG, Peroxidase</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Vector Laboratories</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#MP-7601; RRID:AB_2336533</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">TSA Plus Fluorescein Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Akoya Biosciences</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#NEL741001KT</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Hematoxylin</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#HHS32</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Refrax Mounting Medium</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Anatech Ltd</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#711</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Fluoromount-G</td>
            <td align="left" valign="top" rowspan="1" colspan="1">SouthernBiotech</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#0100&#8211;01</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">cOmplete ULTRA Protease Inhibitor Cocktail</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Roche</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#5892970001</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Pierce BCA Protein Assay Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#23227</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Simple Western Quantitative Immunoassay (Wes) 12&#8211;230 kDa Plates</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ProteinSimple</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#SM-W004</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Wes anti-Rabbit Secondary Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ProteinSimple</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#DM-001</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">NEBNext Ultra II Q5 Master Mix</td>
            <td align="left" valign="top" rowspan="1" colspan="1">New England Biolabs</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#M0544L</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Sera-Mag Select Beads</td>
            <td align="left" valign="top" rowspan="1" colspan="1">GE Healthcare Life Sciences</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#29343052</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Agilent High Sensitivity DNA Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Agilent Technologies</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#5067&#8211;4626</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Agilent 2100 Bioanalyzer</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Agilent Technologies</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#G2939BA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">PEN Membrane Slides</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#LCM0522</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Arcturus XT LCM System</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#A26818</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">CapSure HS LCM Caps</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#LCM0215</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">PicoPure DNA Extraction Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#KIT0103</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">AMPure XP Beads</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Beckman Coulter</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#A63880</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Qubit dsDNA HS Assay Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#Q32851</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">MinElute PCR Purification Kit</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Qiagen</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cat#28006</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" style="border-bottom: solid 1px; border-top: solid 1px" rowspan="1">Deposited data</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">RNA-seq, LCM sequencing, and Tuba-seq data</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">GEO: GSE198637</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">CyTOF data</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cytobank Community: <ext-link ns1:href="https://community.cytobank.org/cytobank/experiments/103066" ext-link-type="uri">https://community.cytobank.org/cytobank/experiments/103066</ext-link></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Source data and images</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Mendeley Data: <ext-link ns1:href="10.17632/nr4ssx645r.2" ext-link-type="doi">https://doi.org/10.17632/nr4ssx645r.2</ext-link></td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" style="border-bottom: solid 1px; border-top: solid 1px" rowspan="1">Experimental models: Cell lines</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H1694</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">CRL-5888; RRID:CVCL_1489</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H146</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">HTB-173; RRID:CVCL_1473</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H2227</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">CRL-5934; RRID:CVCL_1542</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H1876</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">CRL-5902; RRID:CVCL_1503</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H889</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">CRL-5817; RRID:CVCL 1598</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H526</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">CRL-5811; RRID:CVCL_1569</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H2081</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">CRL-5920; RRID:CVCL_1522</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H446</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">HTB-171; RRID:CVCL_1562</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H524</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">CRL-5831; RRID:CVCL_1568</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H82</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ATCC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">HTB-175; RRID:CVCL_1591</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H82-epicTAG-GFP-StrepTagII-ProtC-HA (EpicTag 1)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Rovira-Clav&#233; et al.<sup><xref rid="R32" ref-type="bibr">32</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H82-epicTAG-GFP-VSVg-StrepTagII-HA (EpicTag 2)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Rovira-Clav&#233; et al.<sup><xref rid="R32" ref-type="bibr">32</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H82-epicTAG-GFP-HA-FLAG-AU1 (EpicTag 3)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Rovira-Clav&#233; et al.<sup><xref rid="R32" ref-type="bibr">32</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H82-epicTAG-GFP-StrepTagII-FLAG-AU1 (EpicTag 4)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Rovira-Clav&#233; et al.<sup><xref rid="R32" ref-type="bibr">32</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H82-epicTAG-GFP-VSVg-ProtC-HA (EpicTag 5)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Rovira-Clav&#233; et al.<sup><xref rid="R32" ref-type="bibr">32</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Human: NCI-H82-epicTAG-GFP-VSVg-StrepTagII-ProtC (EpicTag 6)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Rovira-Clav&#233; et al.<sup><xref rid="R32" ref-type="bibr">32</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse: KP11</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Sen et al.<sup><xref rid="R57" ref-type="bibr">57</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse: KP22</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Denny et al.<sup><xref rid="R26" ref-type="bibr">26</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse: 12N1G</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Denny et al.<sup><xref rid="R26" ref-type="bibr">26</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse: N2N1G</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Denny et al.<sup><xref rid="R26" ref-type="bibr">26</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse: LSL-YFP mouse embryonic fibroblasts</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Rogers et al.<sup><xref rid="R20" ref-type="bibr">20</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Cell lines generated from this paper, please see <xref rid="SD2" ref-type="supplementary-material">Table S7</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" style="border-bottom: solid 1px; border-top: solid 1px" rowspan="1">Experimental models: Organisms/strains</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse: <italic toggle="yes">RPR2</italic> model</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Schaffer et al.<sup><xref rid="R11" ref-type="bibr">11</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse: <italic toggle="yes">RPR2T</italic></td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse: <italic toggle="yes">RPR2T</italic>;<italic toggle="yes">Cas9</italic></td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse: <italic toggle="yes">RP</italic> model</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Schaffer et al.<sup><xref rid="R11" ref-type="bibr">11</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse: <italic toggle="yes">RPT</italic>;<italic toggle="yes">Cas9</italic></td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse: <italic toggle="yes">RPM</italic> model</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Mollaoglu et al.<sup><xref rid="R7" ref-type="bibr">7</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mouse: <italic toggle="yes">RPMT</italic>;<italic toggle="yes">Cas9</italic></td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" style="border-bottom: solid 1px; border-top: solid 1px" rowspan="1">Oligonucleotides</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Primers for Tuba-seq vectors, please see <xref rid="SD2" ref-type="supplementary-material">Table S9</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" style="border-bottom: solid 1px; border-top: solid 1px" rowspan="1">Recombinant DNA</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pCMV-VSV-G</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Stewart et al.<sup><xref rid="R58" ref-type="bibr">58</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #8454</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pCMV-dR8.2 dvpr</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Stewart et al.<sup><xref rid="R58" ref-type="bibr">58</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #8455</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-EFS-EGFP-T2A-Bsd</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193198</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-EFS-hTSC1-T2A-Bsd</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193199</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgNeo/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Chiou et al.<sup><xref rid="R59" ref-type="bibr">59</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #67594</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgNeo2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Rogers et al.<sup><xref rid="R20" ref-type="bibr">20</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #89652</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgNeo3/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Rogers et al.<sup><xref rid="R20" ref-type="bibr">20</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #89653</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgNT/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Chiou et al.<sup><xref rid="R59" ref-type="bibr">59</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #66895</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgNT.2#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173661</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgAdgb#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193200</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgAdgb#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193201</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgAmbra1#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Chaikovsky et al.<sup><xref rid="R61" ref-type="bibr">61</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgAmbra1#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Chaikovsky et al.<sup><xref rid="R61" ref-type="bibr">61</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgAmbra1#3/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Chaikovsky et al.<sup><xref rid="R61" ref-type="bibr">61</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgApc/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Rogers et al.<sup><xref rid="R20" ref-type="bibr">20</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #89641</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgApc#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193202</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgArid1a#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173571</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgArid1a#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173572</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgArid1b#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173573</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgArid1b#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173574</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgAtrx#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173612</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgAtrx#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173616</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgBrca2#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173627</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgBrca2#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173628</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgBrip1#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193203</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgBrip1#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193204</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgCdkn2a#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173629</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgCdkn2a#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173630</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgCol11a1#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193205</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgCol11a1#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193206</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgCol22a1#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193207</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgCol22a1#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193208</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgCrebbp#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193209</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgCrebbp#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193210</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgEp300#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173591</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgEp300#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173592</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgErich3#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193211</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgErich3#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193212</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgFam135b#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193213</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgFam135b#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193214</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgFat1#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173633</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgFbxw7#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173635</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgFbxw7#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173636</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgFlt4#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193215</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgFlt4#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193216</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgGrin2a#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193217</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgHcn1#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193218</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgKdm6a#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173637</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgKdm6a#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173638</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgKmt2c#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173652</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgKmt2d#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173597</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgKmt2d#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173598</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgLrp1b#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173641</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgLrp1b#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173642</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgMroh2b#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193219</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgMroh2b#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193220</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgNkx2-1#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193221</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgNkx2-1#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193222</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgNotch1#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193223</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgNotch1#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193224</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgNotch2#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193225</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgNotch2#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193226</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgNotch3#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193227</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgNotch3#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193228</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgPcdh15#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193229</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgPcdh15#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193230</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgPcna#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Tang et al.<sup><xref rid="R62" ref-type="bibr">62</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgPrdm9#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193231</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgPrdm9#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193232</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgPten#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cai et al.<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #173645</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgRb1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Rogers et al.<sup><xref rid="R20" ref-type="bibr">20</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #89647</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgRb1#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Chaikovsky et al.<sup><xref rid="R61" ref-type="bibr">61</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgRos1#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193233</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgRos1#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193234</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgRunx1t1#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193235</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgRunx1t1#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193236</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgSis#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193237</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgSis#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193238</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgSpen#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193239</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgSpen#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193240</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgSphkap#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193241</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgTmem132d#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193242</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgTmem132d#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193243</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgTnr#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193244</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgTnr#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193245</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgTsc1#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193246</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgTsc1#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193247</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgZfp536#1/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193248</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Plasmid: Lenti-sgZfp536#2/Cre</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Addgene Plasmid #193249</td>
          </tr>
          <tr>
            <td colspan="3" align="left" valign="top" style="border-bottom: solid 1px; border-top: solid 1px" rowspan="1">Software and algorithms</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">LAS X v3.7.1</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Leica Microsystems</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<ext-link ns1:href="https://www.leica-microsystems.com/products/microscope-software/p/leica-las-x-ls/" ext-link-type="uri">https://www.leica-microsystems.com/products/microscope-software/p/leica-las-x-ls/</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Fiji v1.53f51</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Schindelin et al.<sup><xref rid="R63" ref-type="bibr">63</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<ext-link ns1:href="https://imagej.net/software/fiji/downloads" ext-link-type="uri">https://imagej.net/software/fiji/downloads</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Compass for SW v5.0.1</td>
            <td align="left" valign="top" rowspan="1" colspan="1">ProteinSimple</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<ext-link ns1:href="https://www.proteinsimple.com/software_compass_simplewestern.html" ext-link-type="uri">https://www.proteinsimple.com/software_compass_simplewestern.html</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Salmon V0.12.0</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Patro et al.<sup><xref rid="R64" ref-type="bibr">64</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<ext-link ns1:href="https://github.com/COMBINE-lab/salmon" ext-link-type="uri">https://github.com/COMBINE-lab/salmon</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">DESeq2 v1.34.0</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Love et al.<sup><xref rid="R65" ref-type="bibr">65</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<ext-link ns1:href="https://bioconductor.org/packages/release/bioc/html/DESeq2.html" ext-link-type="uri">https://bioconductor.org/packages/release/bioc/html/DESeq2.html</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">ClueGo v2.5.6</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Bindea et al.<sup><xref rid="R66" ref-type="bibr">66</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<ext-link ns1:href="https://apps.cytoscape.org/apps/cluego" ext-link-type="uri">https://apps.cytoscape.org/apps/cluego</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Cytoscape v3.8.0</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Shannon et al.<sup><xref rid="R67" ref-type="bibr">67</xref></sup></td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<ext-link ns1:href="https://cytoscape.org/download.html" ext-link-type="uri">https://cytoscape.org/download.html</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">GraphPad Prism v9.1.0</td>
            <td align="left" valign="top" rowspan="1" colspan="1">GraphPad Software</td>
            <td align="left" valign="top" rowspan="1" colspan="1">
<ext-link ns1:href="https://www.graphpad.com/scientific-software/prism/" ext-link-type="uri">https://www.graphpad.com/scientific-software/prism/</ext-link>
</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Code for LCM Barcode clonality analysis, meta-analysis, and RNA-seq analysis</td>
            <td align="left" valign="top" rowspan="1" colspan="1">This paper</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><ext-link ns1:href="https://github.com/noahlee577/SCLC_Tuba-seq" ext-link-type="uri">https://github.com/noahlee577/SCLC_Tuba-seq</ext-link>, archived at Zenodo: <ext-link ns1:href="10.5281/zenodo.7430243" ext-link-type="doi">https://doi.org/10.5281/zenodo.7430243</ext-link></td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <boxed-text id="BX1" position="float">
      <caption>
        <title>Highlights</title>
      </caption>
      <list list-type="bullet" id="L2">
        <list-item>
          <p id="P98">A meta-analysis identifies candidate drivers of SCLC, including mTOR signaling</p>
        </list-item>
        <list-item>
          <p id="P99">Naphthalene enhances SCLC development upon lentiviral infection in mouse models</p>
        </list-item>
        <list-item>
          <p id="P100">Implementation of Tuba-seq in a mouse model of SCLC validates cancer drivers</p>
        </list-item>
        <list-item>
          <p id="P101">TSC1 is a tumor suppressor in mice and humans with SCLC</p>
        </list-item>
      </list>
    </boxed-text>
  </floats-group>
</article>
</pmc-articleset>